EPICORE Embase Updates: EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 65

Results Generated From:
Embase <1980 to 2025 Week 07>
Embase Weekly Updates (updates since 2025-02-07)

<1>
Accession Number
2036880984
Title
The impact of white matter lesions and subclinical cerebral ischemia on
postoperative cognitive training outcomes after heart valve surgery: A
randomized clinical trial.
Source
Journal of the Neurological Sciences. 469 (no pagination), 2025. Article
Number: 123370. Date of Publication: 15 Feb 2025.
Author
Butz M.; Gerriets T.; Sammer G.; El-Shazly J.; Braun T.; Sunner L.; Meyer
R.; Tschernatsch M.; Schramm P.; Gerner S.T.; Doeppner T.R.; Mengden T.;
Choi Y.-H.; Schoenburg M.; Juenemann M.
Institution
(Butz, Gerriets, Sammer, Braun, Sunner, Meyer, Tschernatsch, Schramm,
Schoenburg, Juenemann) Heart and Brain Research Group, Kerckhoff Heart and
Thorax Center, Bad Nauheim, Germany
(Butz, Gerriets, Braun, Meyer, Tschernatsch, Schramm, Gerner, Doeppner,
Juenemann) Department of Neurology, University Hospital Giessen and
Marburg, Giessen, Germany
(Butz) Department of Geriatrics, Health Center Wetterau, Schotten, Germany
(Gerriets, Tschernatsch) Die Neurologen, Private Neurology Practice, Bad
Nauheim, Germany
(Sammer) Cognitive Neuroscience at the Center of Psychiatry, Justus-Liebig
University, Giessen, Germany
(Sammer) Department of Psychology, Justus-Liebig University, Giessen,
Germany
(El-Shazly) Department of Psychocardiology, Kerckhoff Heart and Thorax
Center, Bad Nauheim, Germany
(Mengden) Department of Rehabilitation, Kerckhoff Heart and Thorax Center,
Bad Nauheim, Germany
(Choi, Schoenburg) Department of Cardiac Surgery, Kerckhoff Heart and
Thorax Center, Bad Nauheim, Germany
Publisher
Elsevier B.V.
Abstract
Background: White matter lesions and subclinical cerebral ischemia (SCI)
are described as risk factors for postoperative cognitive decline (POCD)
following cardiac surgery. This report aims to investigate the effect of
brain lesions on postoperative cognitive training outcomes.
 Method(s): In a randomized, treatment-as-usual controlled trial,
elderly patients scheduled for elective heart valve surgery participated.
The postoperative cognitive training comprised paper-and-pencil exercises.
Neuropsychological parameters were assessed preoperatively, at discharge
from rehabilitation (immediately post-training), and at the 3-month
follow-up. In addition, depression and anxiety (HADS) as well as
health-related quality of life (SF-36) were evaluated. Brain lesions were
identified using magnetic resonance imaging (training group: n = 18;
control group: n = 21). Specifically, periventricular white matter lesions
(PVWML) and deep white matter lesions (DWML) were assessed using
T2-weighted/FLAIR sequences and categorized according to Fazekas scale.
Volumetric analysis of SCI was conducted using diffusion-weighted imaging.
To statistically control the impact of brain lesions on training outcomes,
we employed analysis of covariance. Result(s): Three-month follow-up
results: When controlling for the independence of SCI on training
outcomes, effects were evident for global cognition (p = 0.022) and SF-36
mental component summary (p = 0.003). Considering the impact of PVWML on
training outcomes, trained participants showed better values in depression
(p = 0.046) and SF-36 mental component summary (p = 0.013). In a subgroup
analysis for patients with PVWML the training group demonstrated superior
performance for language (p = 0.037). After adjusting for DWML, training
effects were noticeable in the SF-36 mental component summary (p = 0.013).
 Conclusion(s): Patients with brain lesions may benefit from cognitive
training after cardiac surgery. Copyright © 2024

<2>
Accession Number
2035420456
Title
Subcostal transversus abdominis plane block for epigastric cardiac
pacemaker operation: A randomised controlled trial.
Source
European Journal of Anaesthesiology. 42(3) (pp 275-278), 2025. Date of
Publication: 01 Mar 2025.
Author
Kim J.-T.; Min J.; Park J.-B.; Jang Y.-E.
Institution
(Kim, Park, Jang) Department of Anaesthesiology and Pain Medicine, Seoul
National University Hospital, Seoul National University College of
Medicine, Seoul, South Korea
(Min) Department of Thoracic and Cardiovascular Surgery, Seoul National
University Hospital, Seoul National University College of Medicine, Seoul,
South Korea
Publisher
Lippincott Williams and Wilkins

<3>
Accession Number
2032666629
Title
Complete versus culprit-only percutaneous coronary intervention in elderly
patients with acute coronary syndrome and multivessel coronary artery
disease: A systematic review and meta-analysis.
Source
Cardiovascular Revascularization Medicine. 70 (pp 1-9), 2025. Date of
Publication: 01 Jan 2025.
Author
Franco A.J.; Krishna M.M.; Joseph M.; Ezenna C.; Bakir Z.E.; Sudo R.Y.U.;
Wippel C.W.; Ismayl M.; Goldsweig A.M.; Uthirapathy I.
Institution
(Franco) Department of Medicine, Sri Muthukumaran Medical College Hospital
and Research Institute, India
(Krishna, Joseph) Department of Medicine, Medical College
Thiruvananthapuram, India
(Ezenna) Department of Medicine, University of Massachusetts - Baystate
Medical Center, Springfield, MA, United States
(Bakir) Department of Medicine, Sapienza University of Rome, Italy
(Sudo) Department of Medicine, Federal University of Grande Dourados,
Brazil
(Wippel) Department of Internal Medicine, Barnes Jewish Hospital,
Washington University School of Medicine, United States
(Ismayl) Department of Cardiovascular Medicine, Mayo Clinic, Rochester,
MN, United States
(Goldsweig) Department of Cardiology, Baystate Medical Center,
Springfield, MA, United States
(Uthirapathy) Department of Interventional Cardiology, Billroth Hospital,
Tamil Nadu, India
Publisher
Elsevier Inc.
Abstract
Background: Culprit-only percutaneous coronary intervention (PCI) is
commonly performed for acute coronary syndrome (ACS) with multivessel
coronary artery disease (MVD) in the elderly. Complete revascularization
has been shown to benefit the general population, yet its safety and
efficacy in older patients are uncertain. Method(s): Following PRISMA
guidelines, we systematically searched PubMed, Embase, and Cochrane
databases for randomized controlled trials (RCTs) comparing complete
versus culprit-only PCI in patients >=65 years old with ACS and MVD. The
primary outcome was major adverse cardiovascular events (MACE). Secondary
outcomes included myocardial infarction (MI), ischemia-driven
revascularization (IDR), all-cause mortality, and cardiovascular
mortality. Data were pooled using a random effects model with a restricted
maximum likelihood estimator to generate risk ratios (RRs).
 Result(s): Five RCTs with 4105 patients aged >=65 years were
included. Compared with culprit-only PCI, complete revascularization
reduced MI (RR 0.65; 95 % CI 0.49-0.85; p < 0.01). MACE (RR 0.75; 95 % CI
0.54-1.05; p = 0.09) and IDR (RR 0.41; 95 % CI 0.16-1.04; p = 0.06) were
not significantly different between both strategies among those aged >=65.
However, there was a significant reduction in MI (RR 0.69; 95 % CI
0.49-0.96; p-value = 0.03), MACE (RR 0.78; 95 % CI 0.65-0.94; p < 0.01),
and IDR (RR 0.60; 95 % CI 0.41-0.89; p < 0.01) in those aged >=75.
 Conclusion(s): In elderly patients aged >=65 years with ACS and MVD,
a strategy of complete revascularization by PCI reduces MI compared to
culprit-only PCI with no significant difference in MACE and IDR. However,
complete revascularization reduced MI, MACE, and IDR in those aged >=75
years suggesting a possible benefit in this age group. Copyright
© 2024 Elsevier Inc.

<4>
Accession Number
2037330812
Title
The Potential Role of Albumin in Reducing Cardiac Surgery-Associated Acute
Kidney Injury: A Randomized Controlled Trial.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 39(2) (pp 453-460),
2025. Date of Publication: 01 Feb 2025.
Author
Miralles Bagan J.; Parrilla Quiles L.; Paniagua Iglesias P.; Betbese Roig
A.J.; Sabate Tenas S.; Perez Garcia S.; Garcia Alvarez M.
Institution
(Miralles Bagan, Parrilla Quiles, Paniagua Iglesias, Sabate Tenas, Perez
Garcia, Garcia Alvarez) Department of Anesthesiology, Reanimation and Pain
Therapy, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
(Betbese Roig) Department of Intensive Care Medicine, Hospital de la Santa
Creu i Sant Pau, Barcelona, Spain
Publisher
W.B. Saunders
Abstract
Objectives: Cardiac surgery-associated acute kidney injury (CSA-AKI) is a
common complication with high morbidity and mortality. This study was
designed to determine whether adding human albumin to the cardiopulmonary
bypass (CPB) priming solution reduces the incidence of CSA-AKI.
 Design(s): A double-blind, randomized controlled trial (RCT)
involving 248 patients scheduled for cardiac surgery with CPB.
 Setting(s): A single-center tertiary university hospital.
 Participant(s): Adults with a baseline estimated glomerular
filtration rate (eGFR) of >=60 mL/min/1.73 m2 and left
ventricular ejection fraction >=40%. Intervention(s): Patients were
randomized to receive either a crystalloid priming solution (Plasma-Lyte)
plus 4% albumin (intervention group, n = 126) or a crystalloid solution
alone (control group, n = 122) for CPB. Measurements and Main
Results: Data analyses were performed using the Chi-square test and
Student's t-test, or their nonparametric equivalent. The primary outcome
was the incidence of CSA-AKI, as defined by the Kidney Disease Improving
Global Outcomes criteria, within 5 days postoperatively. Both cohorts were
comparable in baseline and perioperative characteristics, including
preoperative albumin levels. The incidence of CSA-AKI was 29.3% (n = 37)
in the intervention group compared with 31.2% (n = 38) in the control
group (odds ratio: 0.91, 95% confidence interval: 0.53-1.58). The observed
difference in CSA-AKI incidence between the groups was not statistically
significant. A post-hoc subgroup analysis of patients with a baseline eGFR
of 60 to 70 mL/min/1.73 m2 indicated a trend toward a reduced incidence of
CSA-AKI in the intervention group compared with the control group (35.7% v
57.6%; odds ratio: 0.41, 95% confidence interval: 0.16-1.03). This trend
was not observed in patients with an eGFR greater than 70 mL/min/1.73 m2.
No significant differences were observed between groups for the need for
inotropes or vasoconstrictors, incidence of cardiogenic or distributive
shock, bleeding, need for transfusion, or use of nephrotoxic drugs.
 Conclusion(s): Adding albumin to the CPB priming solution did not
decrease the incidence of CSA-AKI in patients with normal preoperative
renal function. These findings suggest that albumin might benefit patients
with impaired renal function, warranting further
investigation. Copyright © 2024 Elsevier Inc.

<5>
Accession Number
2035578088
Title
To Assess the Impact of Glucose, Insulin, and Potassium Chloride Infusions
in Patients after Cardiothoracic Surgery on Arrhythmias and Outcome.
Source
Journal of Cardiac Critical Care. 9(1) (pp 29-34), 2025. Date of
Publication: 01 Jan 2025.
Author
Tharra L.; Parveen N.; Dikshit V.; Subba Reddy K.; Sirga S.; Venturumilli
R.S.
Institution
(Tharra, Parveen, Subba Reddy, Sirga) Department of Critical Care, Apollo
Hospital, Telangana, Hyderabad, India
(Dikshit, Venturumilli) Department of Cardiac Surgery, Apollo Hospital,
Telangana, Hyderabad, India
Publisher
Scientific Scholar LLC
Abstract
Objectives: The role of glucose, insulin, and potassium chloride (GIK)
infusions on arrhythmias after cardiothoracic surgery was widely studied.
Optimization of myocardial glucose uptake, ischemia damage, and
arrhythmias is reduced by GIK infusion. Most of the research was conducted
when GIK infusion was utilized intraoperatively. Studies done to know the
impact of GIK infusions on rhythm issues after cardiothoracic surgery were
contradictory, some studies showed positive results whereas other studies
indicated that GIK solution usage after cardiothoracic surgery has no role
in preventing arrhythmias. Therefore, the use of GIK infusion to prevent
arrhythmias in patients recovering from cardiac surgery is still
debatable, necessitating the completion of additional research before a
conclusion can be drawn. (1) Primary objective: To determine whether GIK
infusions can prevent arrhythmias after cardiac surgery. (2) Secondary
objective: To know outcome parameters such as inotropic requirement,
ventilatory hours, stay in Intensive Care Unit (ICU). Material(s) and
Method(s): This is a randomized control trail including patients of both
sexes aged 20-60 years, who were shifted to post-operative cardiothoracic
ICU unit of Apollo Multi-specialty Hospital (Jubilee hills, Hyderabad),
after undergoing cardiothoracic surgery (Coronary artery bypass graft and
valve replacement or repair). The study was done from June 2023 to
February 2024. Following the fulfillment of the relevant inclusion
criteria, a total of 100 patients were assigned to two groups equally: The
study GIK and control (non-GIK) groups through computer-based
randomization. Once the patient is shifted to post-operative
cardiothoracic unit after cardiac surgery, GIK infusion (40 IU/L of human
actrapid and 40 meq/L potassium chloride was added to 10% dextrose
solution) is given to the GIK group, with flow rate of 30 mL/h. The
infusion continued for 48 h following surgery. In non-GIK group, normal
saline or other intravenous fluid was started as per requirement.
 Result(s): The demographic characteristics of the study group (GIK
group) and control group (non-GIK group) are similar. The control group
was observed to have more arrhythmias compared to the study GIK group with
a significant P < 0.001. The odds ratio is 0.1976 and confidence interval
95% between the two groups is 0.084-0.465. The incidence of atrial
fibrillation was high among all arrhythmias in non GIK group, while the
GIK group had a higher incidence of premature ventricular contractions.
The non-GIK group experienced longer ionotropic support than the study
group (GIK group) with significant P < 0.001. The non-GIK group had higher
rates of ventilatory support requirements and increased duration of ICU
stay (P = 0.002 and <0.001). Significant side effects were not observed
with GIK infusion. Conclusion(s): GIK infusion after cardiac surgery
helps to minimize post-operative arrhythmias and is linked to better
post-operative outcomes, such as lower requirement of ionotropic support
and early extubation leading to decreased length of stay in the ICU. There
are no noteworthy non-cardiac problems linked to the use of
GIK. Copyright © 2025 Published by Scientific Scholar on behalf
of Journal of Cardiac Critical Care TSS.

<6>
Accession Number
2037344870
Title
Comparison of Provisional 1-Stent Strategy With Drug-Eluting Balloon
Versus Planned 2-Stent Strategy in Patients With Non-LM Coronary
True-Bifurcation Lesions (PROVISION-DEB).
Source
American Journal of Cardiology. 242 (pp 18-23), 2025. Date of Publication:
01 May 2025.
Author
Choi S.-S.; Jung J.; Kim K.; Her S.-H.; Lee K.; Jeon D.-S.; Hwang B.-H.;
Park C.S.; Lim S.; Seo S.M.; Mok J.; Han S.H.; Kwon S.U.; Hahn J.-Y.; Lee
S.-W.; Choi W.G.
Institution
(Choi, Jung, Kim, Her) Department of Cardiology, St. Vincent's Hospital,
College of Medicine, The Catholic University of Korea, Seoul, South Korea
(Lee) Department of Cardiology, Daejeon St. Mary's Hospital, College of
Medicine, The Catholic University of Korea, Seoul, South Korea
(Jeon) Department of Cardiology, Incheon St. Mary's Hospital, College of
Medicine, The Catholic University of Korea, Seoul, South Korea
(Hwang) Cardiovascular Center and Cardiology Division, Seoul St. Mary's
Hospital, The Catholic University of Korea, Seoul, South Korea
(Park) Cardiovascular Center and Cardiology Division, Yeouido St. Mary's
Hospital, The Catholic University of Korea, Seoul, South Korea
(Lim) Cardiovascular Center and Cardiology Division, Uijeongbu St. Mary's
Hospital, The Catholic University of Korea, Seoul, South Korea
(Seo) Department of Cardiology, Eunpyeong St. Mary's Hospital, College of
Medicine, The Catholic University of Korea, Seoul, South Korea
(Mok) Department of Cardiology, Bucheon St. Mary's Hospital, College of
Medicine, The Catholic University of Korea, Seoul, South Korea
(Han) Gachon University Gil Medical Center, Incheon, South Korea
(Kwon) Department of Cardiology, Ilsan-Paik Hospital, Inje University
College of Medicine, Goyang, South Korea
(Hahn) Heart Vascular Stroke Institute, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul, South Korea
(Lee) Department of Cardiology, Asan Medical Center, University of Ulsan
College of Medicine, Seoul, South Korea
(Choi) Department of Cardiology, College of Medicine, Chungbuk National
University, Cheongju, South Korea
Publisher
Elsevier Inc.
Abstract
Percutaneous coronary intervention (PCI) for bifurcation lesions presents
several difficulties and often results in suboptimal procedural,
postprocedural clinical outcomes. While the provisional 1-stent strategy
is generally favored for its simplicity and favorable outcomes, a few
studies suggest no significant difference between 1-stent and 2-stent
techniques for true bifurcation lesions. Drug-eluting balloons (DEBs) have
demonstrated potential in small vessel disease, including bifurcation side
branches. However, no studies have compared the 2-stent strategy with the
provisional 1-stent plus DEB strategy in non-LM true bifurcation lesions.
Our study aims to address this gap by comparing these strategies, with a
focus on real-world practice and detailed endpoint analysis. The
PROVISION-DEB study is an open-label, randomized, multicenter clinical
trial designed to investigate noninferiority and compare a 1-stent
strategy with a drug-eluting balloon and a planned 2-stent strategy at
non-LM coronary true-bifurcation lesions. A total of 750 patients with de
novo non-LM coronary bifurcation lesions undergoing coronary interventions
will be randomized 1:1 to either a provisional 1-stent plus DEB strategy
or a 2-stent strategy with stratified Diabetes. The primary endpoint is a
target lesion failure, composite outcome of cardiac death, target vessel
myocardial infarction, or target lesion revascularization at the
anticipated 3 years follow-up (6, 12, and 36 months). In conclusion,
PROVISION-DEB study is a randomized, multicenter, noninferior clinical
trial and will compare a 1-setnt strategy with a drug-eluting balloon and
a planned 2-stent strategy at non-LM coronary
true-bifurcation. Copyright © 2025 The Author(s)

<7>
Accession Number
2033080439
Title
Phenomapping the Response of Patients With Ischemic Cardiomyopathy With
Reduced Ejection Fraction to Surgical Revascularization.
Source
Clinical Cardiology. 48(2) (no pagination), 2025. Article Number: e70094.
Date of Publication: 01 Feb 2025.
Author
Satish T.; Hendren N.S.; Peltz M.; Heid C.A.; Farr M.; Bavry A.; Girotra
S.; Kumbhani D.J.; Drazner M.H.; Tang W.H.W.; Grodin J.L.
Institution
(Satish, Hendren, Peltz, Heid, Farr, Bavry, Girotra, Kumbhani, Drazner,
Grodin) Department of Internal Medicine, Division of Cardiology,
University of Texas Southwestern Medical Center, Dallas, TX, United States
(Tang) Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland,
OH, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Coronary artery bypass grafting (CABG) has demonstrated
long-term mortality benefits in patients with HFREF and obstructive
coronary artery disease (CAD), but whether phenotypic heterogeneity
influences the benefits of CABG is unknown. We applied clustering analysis
to STICHES (Surgical Treatment for Ischemic Heart Failure Extension Study)
to identify phenogroups with different long-term risk profiles and
investigate differences in CABG benefits between phenogroups. Methods
and Results: STICHES was a randomized controlled trial evaluating the
effect of CABG in addition to medical therapy versus medical therapy
alone. We split the STICHES participants into derivation (n = 753) and
validation (n = 459) cohorts. We phenomapped the derivation cohort using
penalized model-based clustering. We fit multivariable Cox models to
investigate long-term differences in all-cause mortality, cardiovascular
(CV) mortality, and a composite of all-cause mortality/CV hospitalization
between phenogroups and whether phenogroup assignment modified the effects
of CABG on these outcomes. Findings were internally validated on the
validation cohort. Four phenogroups were identified in the derivation
cohort. The highest-risk group was at a twofold greater risk of death (HR:
2.0, 95% CI: 1.4-2.9, p < 0.001) and CV death (HR: 2.0, 95% CI: 1.3-3.1, p
= 0.002), and a 1.5-fold greater risk for death/CV hospitalization (HR:
1.5, 95% CI: 1.1-2.1, p = 0.016). Phenogroup assignment did not modify the
effects of CABG on the outcomes (p > 0.05 for all). Similar results were
obtained in the validation cohort. Conclusion(s): The beneficial
effects of CABG on all-cause mortality, CV mortality, and a composite of
all-cause mortality and CV hospitalization persist despite phenotypic
heterogeneity in HFREF and CAD. Copyright © 2025 The Author(s).
Clinical Cardiology published by Wiley Periodicals, LLC.

<8>
Accession Number
2037204338
Title
Exploratory study of patients' and carers' preferences for postdischarge
surgical wound monitoring using survey and interviews.
Source
BMJ Open. 15(1) (no pagination), 2025. Article Number: e087320. Date of
Publication: 25 Jan 2025.
Author
Tanner J.; Brierley Jones L.; Westwood N.; Rochon M.; Wloch C.; Rogers
L.J.; Vaja R.; Dearling J.; Wilson K.; Harrington P.; Brown C.S.; Murphy
G.
Institution
(Tanner) University of Nottingham, Nottingham, United Kingdom
(Brierley Jones) School of Health and Life Sciences, Teesside University,
Middlesbrough, United Kingdom
(Westwood) NottinghamUnited Kingdom
(Rochon, Vaja) Guy's and St Thomas' NHS Foundation Trust, London, United
Kingdom
(Wloch, Harrington, Brown) UK Health Security Agency, London, United
Kingdom
(Rogers) Peter Munk Cardiac Surgery Centre, Toronto General Hospital,
Toronto, ON, Canada
(Dearling) Patient and Public Advisor, King's Lynn, United Kingdom
(Wilson) Liverpool Heart and Chest Hospital NHS Foundation Trust,
Liverpool, United Kingdom
(Murphy) University of Leicester, College of Medicine Biological Sciences
and Psychology, Leicester, United Kingdom
Publisher
BMJ Publishing Group
Abstract
Objectives To explore patients' and carers' preferences for postdischarge
surgical wound monitoring. Design Explanatory mixed methods study with an
online survey followed by online interviews. Setting The online survey was
distributed via the Cardiothoracic Interdisciplinary Research Network and
cardiac surgery patient and public involvement groups in London and
Leicester, UK. Participants were invited to share the survey link with
other patients and carers. Interviewees were recruited through the survey.
Participants Seventy participants completed the survey: 74% patients and
26% carers. A range of ages, sex, ethnicities and geographical locations
were represented. Six survey patient participants volunteered to be
interviewed. Findings Themes identified were the impact on patients of
having a surgical site infection, patients' preferences for postdischarge
surgical wound follow-up, access to specialist support, wound monitoring
using digital technology and receiving information from the hospital about
wounds and wound care. Interviewees described feeling isolated after
discharge from hospital and 10% of survey patient respondents, including
four of the six interviewees, reported hospital readmissions. Survey
respondents' preferred routes for providing hospitals with wound
information were over the telephone (30%), emails (24%), text messages
(16%) and photos sent securely (14%). All six interviewees' preference was
for digital approaches using images. Survey respondents were least likely
(50%) to reply to questionnaires that required software to be downloaded
and installed. Interviewees considered digital wound monitoring to be
convenient and the best use of patient and staff resources. A new theme
was identified where patients wanted to become more involved in treating
their surgical wounds at home. Conclusion Experiences described by
participants suggests there is a need to improve post-discharge wound
monitoring. A new approach should be proactive, ongoing and provide easy
access to healthcare services. Digital surgical wound monitoring offers
these benefits and is acceptable to patients. Copyright © 2025
BMJ Publishing Group. All rights reserved.

<9>
Accession Number
2035578089
Title
Soluble Urokinase Plasminogen Activated Receptor in Type 2 Diabetes
Mellitus Patients Undergoing Coronary Artery Bypass Grafting: A
Prospective Interventional Cohort Study.
Source
Journal of Cardiac Critical Care. 9(1) (pp 35-43), 2025. Date of
Publication: 01 Jan 2025.
Author
Prakash M.; Mujahid O.M.; Choudhury M.
Institution
(Prakash, Mujahid, Choudhury) Department of Cardiac Anaesthesia and
Critical Care, All India Institute of Medical Sciences, New Delhi, India
Publisher
Scientific Scholar LLC
Abstract
Objectives: Elevated levels of soluble urokinase plasminogen activator
receptor (suPAR) increase mortality in various systemic diseases. This has
been shown amply in recent literature. The primary aim of the study was to
investigate that whether this increase in suPAR levels have same results
in type 2 diabetes mellitus (T2DM) patients undergoing coronary artery
bypass grafting (CABG). We also aimed to observe the duration of
mechanical ventilation and length of stay in the intensive care unit in
these patients as our secondary aim. Material(s) and Method(s): Blood
samples of adult patients having T2DM admitted for elective on-pump CABG
surgery were collected after induction of anesthesia before skin incision
(T1) and 48 h post-cardiopulmonary bypass (CPB) (T2) from the year 2022 to
2023. The study was conducted on 196 patients of either sex of age at
least 18 years with T2DM with the American Society of Anesthesiologists
status III to IV. Patients were randomly divided into 2 groups with
alternative allocation. Patients of the study group (n = 96) were measured
suPAR, high-sensitivity C-reactive protein (hsCRP), and blood sugar, while
patients of the control group (n = 100) were measured hsCRP and blood
sugar only. Threshold suPAR levels for predicting mortality in the
immediate postoperative period were assessed through receiver operating
characteristic curves and optimal values decided using Youden's Index.
 Result(s): There was a significant rise in suPAR and hs-CRP levels
before the start of surgery and 48 h post-CPB (P < 0.001).
 Conclusion(s): In patients with T2DM undergoing on-pump CABG,
increased pre-bypass, and especially 48-h post-CPB, levels of suPAR and
hsCRP predict more mortality. Copyright ©2025 Published by
Scientific Scholar on behalf of Journal of Cardiac Critical Care TSS.

<10>
Accession Number
2037265255
Title
Impact of sex-specific thresholds for low flow in assessment of prognosis
in concordantly and discordantly graded aortic valve stenosis.
Source
European Heart Journal Cardiovascular Imaging. 26(2) (pp 280-286), 2025.
Date of Publication: 01 Feb 2025.
Author
Bahlmann E.; Gerdts E.; Einarsen E.; Midtbo H.; Pedersen E.R.; Rossebo A.;
Willems S.; Cramariuc D.
Institution
(Bahlmann, Willems) Department of Cardiology, Asklepios Clinic St. Georg,
Lohmuhlenstrasse 5, Hamburg, Germany
(Gerdts, Midtbo, Pedersen, Cramariuc) Department of Clinical Science,
University of Bergen, Bergen, Norway
(Einarsen) Department of Medicine, Nordland Hospital Trust, Vesteralen
Hospital, Stokmarknes, Norway
(Rossebo) Department of Cardiology, Oslo University Hospital, Ulleval,
Oslo, Norway
(Cramariuc) Department of Heart Disease, Haukeland University Hospital,
Bergen, Norway
Publisher
Oxford University Press
Abstract
Aims Sex-specific low flow was recently defined as stroke volume index
(SVi) <= 40 mL/m2 in men and <=32 mL/m2 in women. We
tested the prognostic association of these cut-offs in patients with
aortic stenosis (AS) with concordantly and discordantly graded AS
[concordantly graded AS by energy loss (CGAS<inf>EL</inf>) and
discordantly graded AS by energy loss (DGAS<inf>EL</inf>)] based on
pressure recovery adjusted aortic valve area [energy loss (EL)]. Methods
Data from 1351 patients with asymptomatic AS, peak jet velocity <4 m/s,
and preserved left ventricular ejection fraction and results enrolled in
the Simvastatin and Ezetimibe in Aortic Stenosis study were used.
DGAS<inf>EL</inf> was defined as EL <1.0 cm2 with mean aortic
gradient <40 mmHg and CGAS<inf>EL</inf> as EL >=1.0 cm2 with
mean aortic gradient <40 mmHg. Patients were further grouped into normal
and low flow. The outcome was combined all-cause death and hospitalization
for heart failure (HF). CGAS<inf>EL</inf> with normal/low flow was present
in 915/253 patients, and DGAS<inf>EL</inf> with normal/low flow was
present in 57/126 patients. During a median follow-up of 4.3 years,
event-free survival was lower in patients with DGAS<inf>EL</inf>
irrespective of flow compared to CGAS<inf>EL</inf> with normal flow (P <
0.05). In Cox regression analysis, DGAS<inf>EL</inf> with normal or low
flow were both associated with increased risk of all-cause death and
hospitalization for HF after adjustment for age, sex, heart rate,
randomized study treatment, hypertension, aortic valve replacement, and
aortic valve calcification (P < 0.05). No survival difference was found
between patients with normal vs. low flow within groups of
DGAS<inf>EL</inf> or CGAS<inf>EL</inf>. Conclusion Identification of low
flow by the proposed sex-specific thresholds of SVi needs more prognostic
validation before application in clinical practice. Copyright ©
The Author(s) 2024.

<11>
Accession Number
2035578110
Title
Recent Improvements in Transfusion Practices in Cardiac Surgery.
Source
Journal of Cardiac Critical Care. 9(1) (pp 4-8), 2025. Date of
Publication: 01 Jan 2025.
Author
Gorlinger K.; Petricevic M.
Institution
(Gorlinger) Department of Anaesthesiology and Intensive Care Medicine,
University Hospital Essen, Essen, Germany
(Petricevic) Department of Cardiac Surgery, University Hospital Center
Split, Split, Croatia
Publisher
Scientific Scholar LLC

<12>
Accession Number
2032549881
Title
Timing of Complete Revascularization Stratified by Index Presentation
During On- and Off-Hours.
Source
American Journal of Cardiology. 223 (pp 73-80), 2024. Date of Publication:
15 Jul 2024.
Author
Elscot J.J.; Kakar H.; den Dekker W.K.; Bennett J.; Sabate M.; Esposito
G.; Boersma E.; Van Mieghem N.M.; Diletti R.
Institution
(Elscot, Kakar, den Dekker, Boersma, Van Mieghem, Diletti) Thorax Center,
Department of Cardiology, Erasmus MC Cardiovascular Institute, Rotterdam,
Netherlands
(Bennett) Department of Cardiovascular Medicine, University Hospital
Leuven, Leuven, Belgium
(Sabate) Interventional Cardiology Department, Cardiovascular Institute,
Hospital Clinic, Barcelona, Spain
(Esposito) Department of Advanced Biomedical Sciences, University of
Naples Federico II, Naples, Italy
Publisher
Elsevier Inc.
Abstract
Recent trials suggested immediate complete revascularization (ICR) as a
safe alternative to staged complete revascularization (SCR), but the
impact of the respective percutaneous coronary intervention strategies
between on- versus off-hours is unclear. On-hours was defined as an index
revascularization performed between 8:00 A.M. and 6:00 P.M., Monday to
Friday, or else the procedure was defined as performed during off-hours.
The primary end point consisted of a composite of all-cause mortality,
myocardial infarction, unplanned ischemia-driven revascularization, and
cerebrovascular events at 1-year follow-up. We used Cox regression models
to relate randomized treatment with study end points. We evaluated
multiplicative and additive interactions between on- versus off-hours and
randomized treatment. The BIOVASC (Percutaneous Complete Revascularization
Strategies Using Sirolimus Eluting Biodegradable Polymer Coated Stents in
Patients Presenting With Acute Coronary Syndromes and Multivessel Disease)
trial enrolled 1,097 and 428 patients during on- and off-hours,
respectively. Patients randomized during off-hours were more likely to
present with ST-segment elevation myocardial infarction (66.4% vs 29.5%, p
<0.001). The composite primary outcome occurred in 8.4% and 10.1% of
patients randomized to ICR and SCR, respectively, during on-hours (hazard
ratio 0.80, 95% confidence interval 0.54 to 1.19). During off-hours, the
primary composite outcome occurred in 5.4% and 7.7% in ICR and SCR (0.69,
95% confidence interval 0.32 to 1.46) with no evidence of a differential
effect (interaction p<inf>multiplicative</inf> = 0.70,
p<inf>additive</inf> = 0.56). No differential effect was found between
treatment allocation and on- versus off-hours in any of the secondary
outcomes. In conclusion, no differential treatment effect was found when
comparing ICR versus SCR in patients presenting with acute coronary
syndrome and multivessel disease during on- or off-hours. Copyright
© 2024 The Authors

<13>
Accession Number
2032545176
Title
Permanent pacemaker reduction using temporary-permanent pacemaker as a
1-month bridge after transcatheter aortic valve replacement: a
prospective, multicentre, single-arm, observational study.
Source
eClinicalMedicine. 72 (no pagination), 2024. Article Number: 102603. Date
of Publication: 01 Jun 2024.
Author
Chang S.; Jiang Z.; Liu X.; Tang Y.; Bai M.; Xu J.; Wang H.; Li C.; Chen
Y.; Liu C.; Dong J.; Luo J.; Li J.; Fu G.; Wang S.; Huang H.; Zhao Y.;
Zhuang X.; Jilaihawi H.; Piazza N.; Yu F.; Modine T.; Song G.
Institution
(Chang, Jiang, Liu, Song) Interventional Center of Valvular Heart Disease,
Beijing AnZhen Hospital, Capital Medical University, National Clinical
Research Centre for Cardiovascular Diseases, Beijing, China
(Tang) Department of Cardiology and Institute of Vascular Medicine, Peking
University Third Hospital, Beijing, China
(Bai, Xu) Department of Cardiology, The First Hospital of Lanzhou
University, Lanzhou, China
(Wang) Department of Cardiology, Qingdao Fuwai Cardiovascular Hospital,
Qingdao, China
(Chen, Li) Department of Emergency Medicine and Chest Pain Center, Qilu
Hospital of Shandong University, Cheeloo College of Medicine Shandong
University, Jinan, China
(Chen, Liu) Senior Department of Cardiology, The Sixth Medical Center of
PLA General Hospital, Beijing, China
(Dong) Department of Cardiology, The First Affiliated Hospital of
Zhengzhou University, Zhengzhou, China
(Luo, Li) Guangdong Provincial People's Hospital, Guangdong Academy of
Medical Sciences, Guangdong Cardiovascular Institute, Guangzhou, China
(Fu, Yu) Department of Cardiology, Sir Run Shaw Hospital, Zhejiang
University of Medicine, Hangzhou, China
(Wang) Department of Cardiology, Fuwai Central China Cardiovascular
Hospital, Zhengzhou, China
(Huang) Department of Cardiology, General Hospital of Ningxia Medical
University, Yinchuan, China
(Zhao) Department of Cardiology, Xuzhou Municipal Hospital Affiliated to
Xuzhou Medical University, Xuzhou, China
(Zhuang) Department of Cardiology, Dalian Municipal Central Hospital,
Dalian, China
(Jilaihawi) NYU Langone Health, New York, United States
(Piazza) Division of Cardiology, Department of Medicine, McGill University
Health Centre, Montreal, QC, Canada
(Modine) UMCV, Hopital Haut Leveque, Centre Hospitalier Universitaire
(CHU) de Bordeaux, France
Publisher
Elsevier Ltd
Abstract
Background: The permanent pacemaker (PPM) implantation and pacemaker
dependency rates after transcatheter aortic valve replacement (TAVR) are
highly variable as some of the conduction disturbances are reversible. It
remains poorly investigated how to optimise temporary pacing in these
patients. This study aimed to explore the potential reduction in the PPM
implantation rate using temporary-permanent pacemaker (TPPM) as a 1-month
bridge. Method(s): This is a prospective, multicentre, single-arm,
observational study. Consecutive patients undergoing TAVR from March 1,
2022 to March 1, 2023 in 13 tertiary hospitals in China were screened.
Patients who developed high-degree atrioventricular block, complete heart
block, or first-degree atrioventricular block plus new onset left bundle
branch block during the TAVR procedure or within 1 month after TAVR were
included to receive TPPM. Patients with pre-existing PPM implantation or
indications for PPM implantation before the TAVR procedure were excluded.
Patients with TPPM were monitored to determine whether the conduction
disturbances persisted or recovered. The primary endpoint was the rate of
freedom from indications for PPM implantation 1 month after TAVR. This
study is registered with ChiCTR, ChiCTR2200057931. Finding(s): Of 688
patients who have undergone TAVR, 71 developed conduction disturbance and
met the inclusion criteria, 1 patient withdrew due to noncompliance, 70
patients received TPPM and completed follow-up. There were 41 (58.6%) men
and 29 (41.4%) women in the study, with a mean age of 74.3 +/- 7.3 years.
At 1 month follow-up, 75.7% (53/70) of the patients with TPPM did not
require PPM implantation. For 688 patients who have undergone TAVR, the
rate of PPM implantation at 1 month was 2.47% (17/688, 95% CI
1.55%-3.92%), representing a significant reduction in self-comparison with
the rate at 48 h after TPPM (2.47% vs. 8.28% [95% CI 6.45%-10.58%], P <
0.0001). Similar results were obtained in the subgroup analysis of
patients with HAVB/CHB. Multivariate analysis revealed the baseline PR
interval, difference between the membranous septum length and implantation
depth, and timing of postprocedural conduction disturbance occurrence were
independent predictors of freedom from indications for PPM implantation at
1 month after TAVR. Interpretation(s): Using TPPM as a 1-month bridge
allows for a buffer period to distinguish whether conduction disturbances
are reversible or persistent, resulting in a significant reduction in the
PPM implantation rate after TAVR when compared with the current strategy.
However, this is an observational study, the results need to be confirmed
in a randomized trial. Funding(s): Beijing Science and Technology
Plan 2022 from Beijing Municipal Science & Technology
Commission. Copyright © 2024 The Author(s)

<14>
Accession Number
2034580994
Title
Liraglutide effects on epicardial adipose tissue micro-RNAs and
intra-operative glucose control.
Source
Nutrition, Metabolism and Cardiovascular Diseases. 35(2) (no pagination),
2025. Article Number: 103726. Date of Publication: 01 Feb 2025.
Author
Iacobellis G.; Goldberger J.J.; Lamelas J.; Martinez C.A.; Sterling C.M.;
Bodenstab M.; Frasca D.
Institution
(Iacobellis, Bodenstab) Division of Endocrinology, Diabetes and
Metabolism, Department of Medicine, University of Miami Miller School of
Medicine, Miami, FL, United States
(Goldberger, Martinez, Sterling) Division of Cardiology, Department of
Medicine, University of Miami Miller School of Medicine, Miami, FL, United
States
(Lamelas) Division of Cardiothoracic Surgery, DeWitt Daughtry Department
of Surgery, University of Miami Miller School of Medicine, Miami, FL,
United States
(Frasca) Department of Microbiology and Immunology, University of Miami
Miller School of Medicine, Miami, FL, United States
(Frasca) Sylvester Comprehensive Cancer Center, University of Miami Miller
School of Medicine, Miami, FL, United States
Publisher
Elsevier B.V.
Abstract
Background and aim: Epicardial adipose tissue (EAT) plays a role in
coronary artery disease (CAD). EAT has regional distribution throughout
the heart and each location may have a different genetic profile and
function. Glucagon like peptide-1 receptor analogs (GLP-1RAs) reduce
cardiovascular risk. However, the short-term effects of GLP-1RA on
microRNA (miRNA) profile of each EAT location is unknown. Objective was to
evaluate if EAT miRNAs were different between coronary (CORO-EAT), left
atrial EAT (LA-EAT) and subcutaneous fat (SAT), and liraglutide can
modulate EAT miRNAs expression. Methods and Results: This was a
12-week randomized, double-blind, placebo-controlled study in 38 patients
with type 2 diabetes (T2DM) and coronary artery disease (CAD) who were
started on either liraglutide or placebo for a minimum of 4 up to 12 weeks
prior to coronary artery by-pass grafting (CABG). Fat samples were
collected during CABG. miR16, miR155 and miR181a were significantly higher
in CORO-EAT and in LA-EAT than SAT (p < 0.01 and p < 0.05) in overall
patients. miR16 and miR181-a were significantly higher in CORO-EAT than
SAT (p < 0.01), and miR155 and miR181a were higher in LA-EAT than SAT (p <
0.05) in the liraglutide group. Liraglutide-treated patients had better
intra-op glucose control than placebo (146 +/- 21 vs 160 +/- 21 mg/dl, p <
0.01). Conclusion(s): Our study shows that CORO- and LA-miRNAs
profiles were significantly different than SAT miRNAs in overall patients
and miRNAs were significantly higher in CORO-EAT and LA-EAT than SAT in
the liraglutide group. Pre-op liraglutide was also associated with better
intra operative glucose control than placebo independently of weight
loss. Copyright © 2024 The Italian Diabetes Society, the Italian
Society for the Study of Atherosclerosis, the Italian Society of Human
Nutrition and the Department of Clinical Medicine and Surgery, Federico II
University

<15>
Accession Number
2037139557
Title
Implications of packed red bloods cells production and transfer on post
transfusion hemoglobin increase.
Source
Journal of Clinical Anesthesia. 102 (no pagination), 2025. Article Number:
111743. Date of Publication: 01 Mar 2025.
Author
Ehrentraut H.; Massoth G.; Delis A.; Thewes B.; Hoch J.; Majchrzak M.;
Weber-Schehl M.; Mayr A.; Abulizi I.; Speller J.; Meybohm P.; Steinisch
A.; Koessler J.; Strauss A.C.; Wittmann M.; Velten M.
Institution
(Ehrentraut, Massoth, Delis, Thewes, Abulizi, Wittmann) Department of
Anesthesiology and Intensive Care Medicine, University Hospital Bonn,
Venusberg-Campus 1, Bonn, Germany
(Hoch) Institute of Hematology and Transfusion Medicine, University
Hospital Bonn, Venusberg-Campus 1, Bonn, Germany
(Majchrzak) German Red Cross Blood Transfusion Service West, Feithstr.
184, Hagen, Germany
(Weber-Schehl) Bavarian Red Cross Blood Donation Service,
Nikolaus-Fey-Str. 32, Wiesentheid, Germany
(Mayr) Department of Medical Biometry and Statistics, University of
Marburg, Hans-Meerwein-Str. 6, Marburg, Germany
(Abulizi, Speller) Institute for Medical Biometry, Informatics and
Epidemiology, University of Bonn, Venusberg-Campus 1, Bonn, Germany
(Meybohm, Steinisch) University Hospital Wurzburg, Department of
Anaesthesiology, Intensive Care, Emergency and Pain Medicine,
Oberdurrbacher Str. 6, Wurzburg, Germany
(Koessler) University Hospital Wurzburg, Institute of transfusion medicine
and hemotherapy, Oberdurrbacher Str. 6, Wurzburg, Germany
(Velten) Department of Anesthesiology and Pain Management, Division of
Cardiovascular and Thoracic Anesthesiology, University of Texas
Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, United
States
(Strauss) Department of Orthopaedic and Trauma Surgery, University Medical
Center Bonn, Bonn, Germany
Publisher
Elsevier Inc.
Abstract
Background: Blood loss resulting in severe anemia is the most common
indication for postoperative allogenic red blood cell (RBC) transfusions.
In high-income countries, the majority of transfusions is received by
elderly patients. Preservatives extend the storage of RBCs, though
concerns exist about potential harm from transfusing older RBCs. This
study tested the hypothesis that RBC storage duration effects hemoglobin
increase in patients older than 70 years who underwent non-cardiac
surgery. Method(s): Observations on surgical cohorts from two study
sites of the LIBERAL-Trial were collected. Transfusion events and
hemoglobin between 2018 and 2022 assessments in addition to manufacturing
and product specific quality review information were evaluated.
 Result(s): A total of 1626 transfusion events in 505 patients were
analyzed. A linear mixed effects model was used to estimate the effect
size of different predictors on hemoglobin increment upon red blood cell
transfusion. No statistically significant effect of the RBC unit storage
duration was found. Confounding variables resulting in higher hemoglobin
increase included lower hemoglobin values prior to transfusion, the length
of Hb measurement intervals before and after transfusion, as well as the
method of RBC cell separation in line with different manufacturer
hemoglobin values. Conclusion(s): The aspired increase in hemoglobin
can be achieved with red blood cell concentrates of any storage duration.
In general, elderly patients exhibit a sufficient hemoglobin rise
following transfusion. However, if this is associated with improved
outcomes cannot be answered. Copyright © 2024

<16>
Accession Number
2035803082
Title
Late gadolinium enhancement on cardiac MRI: A systematic review and
meta-analysis of prognosis across cardiomyopathies.
Source
International Journal of Cardiology. 419 (no pagination), 2025. Article
Number: 132711. Date of Publication: 15 Jan 2025.
Author
Helali J.; Ramesh K.; Brown J.; Preciado-Ruiz C.; Nguyen T.; Silva L.T.;
Ficara A.; Wesbey G.; Gonzalez J.A.; Bilchick K.C.; Salerno M.; Robinson
A.A.
Institution
(Helali, Preciado-Ruiz, Silva, Ficara, Wesbey, Gonzalez, Robinson)
Division of Cardiology, Scripps Clinic, La Jolla, CA, United States
(Ramesh) University of California San Diego School of Medicine, La Jolla,
CA, United States
(Brown) Northwestern University Feinberg School of Medicine, Chicago, IL,
United States
(Nguyen) University of California Riverside, Riverside, CA, United States
(Silva) University of California San Diego, La Jolla, CA, United States
(Bilchick) Department of Cardiovascular Medicine, University of Virginia
Health System, Charlottesville, VA, United States
(Salerno) Department of Medicine, Division of Cardiovascular Medicine,
Stanford University School of Medicine, Stanford, CA, United States
(Wesbey, Gonzalez) Department of Radiology, Scripps Clinic, La Jolla, CA,
United States
Publisher
Elsevier Ireland Ltd
Abstract
Background: Late gadolinium enhancement (LGE) on cardiac MRI has been
shown to predict adverse outcomes in a range of cardiac diseases. However,
no study has systematically reviewed and analyzed the literature across
all cardiac pathologies including rare diseases. Method(s): PubMed,
EMBASE and Web of Science were searched for studies evaluating the
relationship between LGE burden and cardiovascular outcomes. Outcomes
included all-cause mortality, MACE, sudden cardiac death, sustained VT or
VF, appropriate ICD shock, heart transplant, and heart failure
hospitalization. Only studies reporting hazards ratios with LGE as a
continuous variable were included. Result(s): Of the initial 8928
studies, 95 studies (23,313 patients) were included across 19 clinical
entities. The studies included ischemic cardiomyopathy (7182 patients, 33
studies), hypertrophic cardiomyopathy (5080 patients, 17 studies),
non-ischemic cardiomyopathy not otherwise specified (2627 patients, 11
studies), and dilated cardiomyopathy (2345 patients, 14 studies). Among 42
studies that quantified LGE by percent myocardium, a 1 % increase in LGE
burden was associated with life-threatening ventricular arrhythmias (LTVA)
with a pooled hazard ratio of 1.04 (CI 1.02-1.05), and MACE with a pooled
hazard ratio of 1.06 (CI 1.04-1.07). The risk of these events was similar
across disease types, with minimal heterogeneity. Conclusion(s):
Despite mechanistic differences in myocardial injury, LGE appears to have
a fairly consistent, dose-dependent effect on risk of LTVA, MACE, and
mortality. These data can be applied to derive a patient's absolute risk
of LTVA, and therefore can be clinically useful in informing decisions on
primary prevention ICD implantation irrespective of the disease
etiology. Copyright © 2024 Elsevier B.V.

<17>
Accession Number
2035578064
Title
Rotational Thromboelastometry Guided Transfusion Protocol Versus Classic
Transfusion Protocol in Reducing Blood Components Transfusion in Adult
Patients Undergoing Elective Cardiac Surgery: A Randomized Clinical Trial.
Source
Sri Lankan Journal of Anaesthesiology. 33(1) (pp 36-45), 2025. Date of
Publication: 2025.
Author
Mahdy A.M.; Al-Taher E.M.; Helmy A.M.; Kamhawy G.A.; Tawadros P.Z.; Fayad
E.A.; Abdel-Ghaffar M.E.E.
Institution
(Mahdy, Al-Taher, Helmy, Kamhawy, Abdel-Ghaffar) Department of Anesthesia
and Intensive Care, Faculty of Medicine, Suez Canal University, Ismailia,
Egypt
(Tawadros) Department of Anesthesia, Surgical Intensive Care, and Pain
Management, Faculty of Medicine, Cairo University, Cairo, Egypt
(Fayad) Department of Cardiothoracic Surgery, Faculty of Medicine, Suez
Canal University, Ismailia, Egypt
Publisher
College of Anaesthesiologists of Sri Lanka
Abstract
Aim This study assessed the role of rotational thromboelastometry
(ROTEM)-guided transfusion protocol in reducing blood product transfusion
during cardiac surgeries. Methodology This randomized, single-blind trial
enrolled 32 patients who were randomized to receive either the
ROTEM-guided transfusion protocol or the classic transfusion protocol. The
primary outcome was the need for blood component transfusion after bypass
and during the initial 24 postoperative hours. Secondary outcomes included
residual heparin after reversal with protamine and blood loss
postoperatively during the first 24 hours. Results While differences in
red blood cell transfusions post-bypass and within the first 24 hours
postoperatively were observed, they were statistically non-significant.
Fresh frozen plasma (FFP) transfusions differed post-bypass, without
statistical significance. However, the ROTEM group had a statistically
significant reduction in FFP units within the first 24 hours
postoperatively (P<0.001). The number of platelet units transfused in the
initial 24 hours postoperatively showed a difference between both groups,
but it was statistically non-significant. However, ROTEM significantly
reduced platelet use post-bypass (P<0.001). Blood loss also differed
between groups but was statistically non-significant. Conclusions The
application of ROTEM-guided transfusion protocol reduces blood product
transfusion (FPP and platelets) in patients undergoing elective cardiac
surgery on cardiopulmonary bypass. Copyright © 2025, College of
Anaesthesiologists of Sri Lanka. All rights reserved.

<18>
Accession Number
2037305775
Title
Cardiac testing choices by physician specialty in the CMR-IMPACT trial.
Source
American Journal of Emergency Medicine. 90 (pp 200-204), 2025. Date of
Publication: 01 Apr 2025.
Author
Supples M.W.; Snavely A.C.; Ashburn N.P.; Koehler L.E.; Stopyra J.P.; Park
C.J.; Vasu S.; Kutcher M.; Hundley G.; Mahler S.A.; Miller C.; Raman S.V.;
Caterino J.M.; Clark C.L.; Jones A.E.; Hall M.E.; Hiestand B.C.
Institution
(Supples, Snavely, Ashburn, Koehler, Stopyra, Mahler, Miller, Hiestand)
Department of Emergency Medicine, Wake Forest School of Medicine,
Winston-Salem, NC, United States
(Snavely) Department of Biostatistics and Data Science, Wake Forest School
of Medicine, Winston-Salem, NC, United States
(Ashburn, Park, Vasu, Kutcher) Section on Cardiovascular Medicine,
Department of Internal Medicine, Wake Forest School of Medicine,
Winston-Salem, NC, United States
(Hundley) Division of Cardiology, Department of Internal Medicine,
Virginia Commonwealth University, Richmond, VA, United States
(Mahler) Department of Epidemiology and Prevention, Wake Forest School of
Medicine, Winston-Salem, NC, United States
(Mahler) Department of Implementation Science, Wake Forest School of
Medicine, Winston-Salem, NC, United States
(Raman) Ohio Health, Columbus, OH, United States
(Caterino) Department of Emergency Medicine, The Ohio State University,
Columbus, OH, United States
(Clark) Department of Emergency Medicine, Corewell Health William Beaumont
University Hospital, Royal Oak, MI, United States
(Jones) Department of Emergency Medicine, University of Mississippi
Medical Center, Jackson, MS, United States
(Hall) Department of Medicine, University of Mississippi Medical Center,
Jackson, MS, United States
Publisher
W.B. Saunders
Abstract
Background: Heterogeneity is observed in the care of patients with chest
pain. We investigate the association of physician specialty and diagnostic
testing among patients admitted for suspected acute coronary syndrome
(ACS). Method(s): This is a secondary analysis of the CMR-IMPACT
multicenter randomized controlled trial in which patients with suspected
ACS were admitted and randomized to undergo invasive angiography or
non-invasive CMR stress imaging. Admitting physician was dichotomized to
interventional cardiologist (IC) or not (e.g. hospitalist). We describe
adherence to protocol and angiography during the index visit by treatment
arm and admitting physician specialty. A generalized estimating equation
accounting for clustering within physician was used to evaluate
significance and adjusted for randomization arm. Result(s): The 258
enrolled patients from 2013 to 2018 had a mean age of 60.7 (SD +/- 10.9)
years, 40.3 % (104/258 were female), and 64.7 % (167/258) were white race.
ICs were the admitting physicians for 50.4 % (130/258) of the patients.
Index angiography was performed more often among patients admitted by IC
versus other physicians, 65.4 % (85/130) versus 53.1 % (68/128),
respectively; aOR 1.75 (95 % CI 1.14-2.68). Among patients randomized to
an invasive strategy, higher protocol adherence was observed in those
admitted by IC [85.3 % (58/68)] versus other physicians [64.5 % (40/62)];
OR 2.82 (95 % CI 1.08-7.38). For patients randomized to the CMR-based
strategy, adherence to protocol was similar for IC [67.7 % (42/62)] and
other physicians [66.7 % (44/66)]; OR 0.82 (95 % CI 0.35-1.94).
 Conclusion(s): Invasive angiography was more frequent among patients
admitted by interventional cardiologists compared to other
physicians. Copyright © 2025 The Authors

<19>
Accession Number
2037275994
Title
Triple-Valve Endocarditis: A Comprehensive Review of the Literature.
Source
Infectious Diseases in Clinical Practice. 33(2) (no pagination), 2025.
Article Number: 1430. Date of Publication: 01 Mar 2025.
Author
Peterson C.J.; Vattikonda K.S.; Heletz I.
Institution
(Peterson, Vattikonda) Department of Internal Medicine, Virginia Tech
Carilion School of Medicine, Roanoke, VA, United States
(Heletz) Virginia Tech Carilion School of Medicine, Cardiology, Roanoke,
VA, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Multivalve endocarditis with triple valve involvement is a rare phenomenon
and presents a unique management challenge to physicians given the paucity
of summative analyses. Google Scholar and PubMed databases were searched
for terms related to triple-valve endocarditis (TVE). Articles published
up until December 31, 2023, were included. We identified 41 published
cases of triple-valve endocarditis. The most common source of infection
was dental/oral (n = 10). Streptococcus spp was the most common organism
isolated (n = 15), followed by Staphylococcus organisms (n = 9). Surgical
intervention occurred in 65.9% (n = 27) of cases, and the most common
surgery was valve replacement (n = 24) followed by valve repair (n = 10).
Endocarditis complications included valvular insufficiency (n = 33) and
heart failure (n = 15). Most patients were discharged from the hospital (n
= 26), but there were 10 in-hospital deaths and 4 discharged to hospice
care. Copyright © 2025 Wolters Kluwer Health, Inc. All rights
reserved.

<20>
Accession Number
2036187274
Title
Untangling Right Ventricular-Pulmonary Artery Coupling and Pulmonary
Hypertension Definitions in Transcatheter Edge-to-Edge Repair.
Source
American Journal of Cardiology. 238 (pp 93-94), 2025. Date of Publication:
01 Mar 2025.
Author
Park K.; Khalili H.
Institution
(Park, Khalili) Memorial Healthcare System, Hollywood, Florida, United
States
(Khalili) Florida Atlantic University, Boca Raton, FL, United States
Publisher
Elsevier Inc.

<21>
Accession Number
2037125846
Title
Coronary CT angiography-guided management of patients with stable chest
pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in
Scotland.
Source
The Lancet. 405(10475) (pp 329-337), 2025. Date of Publication: 25 Jan
2025.
Author
Williams M.C.; Wereski R.; Tuck C.; Adamson P.D.; Shah A.S.V.; van Beek
E.J.R.; Roditi G.; Berry C.; Boon N.; Flather M.; Lewis S.; Norrie J.;
Timmis A.D.; Mills N.L.; Dweck M.R.; Newby D.E.
Institution
(Williams, Wereski, Tuck, van Beek, Boon, Mills, Dweck, Newby) British
Heart Foundation Centre of Research Excellence, University of Edinburgh,
Edinburgh, United Kingdom
(Williams, van Beek, Newby) Edinburgh Imaging, University of Edinburgh,
Edinburgh, United Kingdom
(Lewis, Mills) Usher Institute, University of Edinburgh, Edinburgh, United
Kingdom
(Lewis) Edinburgh Clinical Trials Unit, University of Edinburgh,
Edinburgh, United Kingdom
(Norrie) Centre for Public Health, Queen's University Belfast, Belfast,
United Kingdom
(Adamson) Christchurch Heart Institute, University of Otago, Christchurch,
New Zealand
(Shah) Department of Non-communicable Disease Epidemiology, London School
of Hygiene & Tropical Medicine, London, United Kingdom
(Roditi, Berry) University of Glasgow, Glasgow, United Kingdom
(Flather) University of East Anglia, Norwich, United Kingdom
(Timmis) Queen Mary University of London, London, United Kingdom
Publisher
Elsevier B.V.
Abstract
Background: The Scottish Computed Tomography of the Heart (SCOT-HEART)
trial demonstrated that management guided by coronary CT angiography
(CCTA) improved the diagnosis, management, and outcome of patients with
stable chest pain. We aimed to assess whether CCTA-guided care results in
sustained long-term improvements in management and outcomes.
 Method(s): SCOT-HEART was an open-label, multicentre, parallel group
trial for which patients were recruited from 12 outpatient cardiology
chest pain clinics across Scotland. Eligible patients were aged 18-75
years with symptoms of suspected stable angina due to coronary heart
disease. Patients were randomly assigned (1:1) to standard of care plus
CCTA or standard of care alone. In this prespecified 10-year analysis,
prescribing data, coronary procedural interventions, and clinical outcomes
were obtained through record linkage from national registries. The primary
outcome was coronary heart disease death or non-fatal myocardial
infarction on an intention-to-treat basis. This trial is registered at
ClinicalTrials.gov (NCT01149590) and is complete. Finding(s): Between
Nov 18, 2010, and Sept 24, 2014, 4146 patients were recruited (mean age 57
years [SD 10], 2325 [56.1%] male, 1821 [43.9%] female), with 2073 randomly
assigned to standard care and CCTA and 2073 to standard care alone. After
a median of 10.0 years (IQR 9.3-11.0), coronary heart disease death or
non-fatal myocardial infarction was less frequent in the CCTA group
compared with the standard care group (137 [6.6%] vs 171 [8.2%]; hazard
ratio [HR] 0.79 [95% CI 0.63-0.99], p=0.044). Rates of all-cause,
cardiovascular, and coronary heart disease death, and non-fatal stroke,
were similar between the groups (p>0.05 for all), but non-fatal myocardial
infarctions (90 [4.3%] vs 124 [6.0%]; HR 0.72 [0.55-0.94], p=0.017) and
major adverse cardiovascular events (172 [8.3%] vs 214 [10.3%]; HR 0.80
[0.65-0.97], p=0.026) were less frequent in the CCTA group. Rates of
coronary revascularisation procedures were similar (315 [15.2%] vs 318
[15.3%]; HR 1.00 [0.86-1.17], p=0.99) but preventive therapy prescribing
remained more frequent in the CCTA group (831 [55.9%] of 1486 vs 728
[49.0%] of 1485 patients with available data; odds ratio 1.17 [95% CI
1.01-1.36], p=0.034). Interpretation(s): After 10 years, CCTA-guided
management of patients with stable chest pain was associated with a
sustained reduction in coronary heart disease death or non-fatal
myocardial infarction. Identification of coronary atherosclerosis by CCTA
improves long-term cardiovascular disease prevention in patients with
stable chest pain. Funding(s): The Chief Scientist Office of the
Scottish Government Health and Social Care Directorates, Edinburgh and
Lothian's Health Foundation Trust, British Heart Foundation, and Heart
Diseases Research Fund. Copyright © 2025 The Author(s). Published
by Elsevier Ltd. This is an Open Access article under the CC BY 4.0
license

<22>
Accession Number
2037326974
Title
Normobaric hyperoxia combined with endovascular treatment for acute
ischaemic stroke in China (OPENS-2 trial): a multicentre, randomised,
single-blind, sham-controlled trial.
Source
The Lancet. 405(10477) (pp 486-497), 2025. Date of Publication: 08 Feb
2025.
Author
Li W.; Lan J.; Wei M.; Liu L.; Hou C.; Qi Z.; Li C.; Jiao L.; Yang Q.;
Chen W.; Liu S.; Yue X.; Dong Q.; Yuan H.; Gao Z.; Wu X.; Wen C.; Li T.;
Jiang C.; Li D.; Chen Z.; Shi J.; Shi W.; Yuan J.; Qin Y.; Li B.; Fisher
M.; Feng W.; Liu K.J.; Ji X.
Institution
(Li, Lan, Wei, Liu, Ji) Beijing Institute of Brain Disorders, Laboratory
of Brain Disorders, Ministry of Science and Technology, Collaborative
Innovation Center for Brain Disorders, Capital Medical University,
Beijing, China
(Hou) Center for Evidence-Based Medicine, Xuanwu Hospital Capital Medical
University, Beijing, China
(Qi) Cerebrovascular Diseases Research Institute, Xuanwu Hospital Capital
Medical University, Beijing, China
(Li) The Stroke Center, Xuanwu Hospital Capital Medical University,
Beijing, China
(Jiao, Ji) Department of Neurosurgery, Xuanwu Hospital Capital Medical
University, Beijing, China
(Yang) Department of Radiology, Beijing Chaoyang Hospital, Capital Medical
University, Beijing, China
(Chen) Department of Neurology, Zhangzhou Affiliated Hospital of Fujian
Medical University, Zhangzhou, China
(Wei, Liu) Department of Neurosurgery, Tianjin Huanhu Hospital, Tianjin,
China
(Yue) Department of Neurocritical Care, Zhoukou Central Hospital, Zhoukou,
China
(Dong, Qin) Department of Emergency Medicine, People's Hospital of Rizhao,
Rizhao, China
(Yuan) Department of Neurology, Qingdao Central Hospital, Qingdao, China
(Gao) Department of Neurology, Central Hospital of Shengli Oil Field,
Dongying, China
(Wu) Department of Neurology, Jiujiang University Affiliated Hospital,
Jiujiang, China
(Wen) Department of Neurology, Nanyang Central Hospital of Xinxiang
Medical University, Nanyang, China
(Li) Department of Neurology, The Second Nanning People's Hospital,
Nanning, China
(Jiang) Department of Neurology, Baotou Central Hospital of Inner Mongolia
Medical University, Baotou, China
(Li) Department of Neurointervention and Neurocritical Care, Dalian
Municipal Central Hospital, Dalian, China
(Chen) Department of Neurosurgery, Shanghai Tenth People's Hospital,
Tongji University School of Medicine, Shanghai, China
(Shi) Cerebrovascular Center, Nanshi Hospital of Nanyang, Nanyang, China
(Shi) Department of Neurosurgery, Peking University Binhai Hospital,
Tianjin, China
(Yuan) Department of Neurology, Beijing Daxing District People's Hospital,
Beijing, China
(Li) Department of Neurology, Jinan Third People's Hospital, Jinan, China
(Fisher) Department of Neurology, Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, MA, United States
(Feng) Department of Neurology, Duke University School of Medicine,
Durham, NC, United States
(Liu) Department of Pathology, Renaissance School of Medicine, Stony Brook
University, Stony Brook, NY, United States
(Ji) State Key Laboratory of Kidney Diseases, Beijing, China
Publisher
Elsevier B.V.
Abstract
Background: Endovascular treatment improves the recanalisation rate for
patients with acute ischaemic stroke; however, even with endovascular
treatment, approximately half of patients do not have a favourable
functional outcome. We aimed to evaluate the effect of normobaric
hyperoxia combined with endovascular treatment on functional outcomes up
to 90 days after treatment in patients who had an acute ischaemic stroke
with large-vessel occlusion. Method(s): In this multicentre,
randomised, single-blind, sham-controlled trial, patients aged 18-80 years
presenting within 6 h of acute ischaemic stroke attributed to large-vessel
occlusion in anterior circulation, who were candidates for endovascular
treatment, were recruited from 26 comprehensive stroke centres in China.
Eligible patients were randomly assigned (1:1), with an Interactive Web
Response System on the basis of a minimisation process to balance
assignment at each participating site both overall and according to age,
sex, occlusion location, and use of intravenous thrombolytics, to receive
either normobaric hyperoxia combined with endovascular treatment or sham
normobaric hyperoxia combined with endovascular treatment. Participants
and assessors were blinded to treatment assignment. Normobaric hyperoxia
treatment involved inhaling 100% oxygen at a flow rate of 10 L/min through
a non-rebreather mask for 4 h, or an inspiratory oxygen fraction
(FiO<inf>2</inf>) of 1.0 in participants for whom intubation was
necessary. Sham treatment was 100% oxygen delivered at a flow rate of 1
L/min or an FiO<inf>2</inf> of 0.3. The primary outcome was the comparison
of the ordinal scores on the modified Rankin Scale (mRS) at 90 days
assessed in the intention-to-treat population (including all patients
randomly assigned to treatment). Safety was assessed in all patients who
received any oxygen therapy. This trial is registered with
ClinicalTrials.gov, NCT04681651, and is now complete. Finding(s):
Between April 22, 2021, and Feb 5, 2023, 473 patients were screened, of
whom 282 were randomly assigned to either normobaric hyperoxia plus
endovascular treatment (n=140) or sham normobaric hyperoxia plus
endovascular treatment (n=142; intention-to-treat population). The median
age was 65 years (IQR 57-71), 75 (27%) of 282 participants were female,
207 (73%) were male, and 282 (100%) of participants were of Chinese Han
ethnicity. At 90 days, the median score on the mRS for the normobaric
hyperoxia group was 2 (IQR 1-4) and it was 3 (1-4) in the sham normobaric
hyperoxia group (adjusted common odds ratio 1.65 [95% CI 1.09-2.50];
p=0.018). At 90 days, 14 (10%) of 140 patients in the normobaric hyperoxia
group and 17 (12%) of 142 in the sham normobaric hyperoxia group died
(adjusted risk difference -0.02 [95% CI -0.09 to 0.06]) and 28 (20%) and
33 (23%) had serious adverse events (adjusted risk difference -0.03 [-0.12
to 0.07]). Interpretation(s): In patients with acute ischaemic stroke
caused by large-vessel occlusion in the anterior circulation who were
candidates for endovascular treatment, normobaric hyperoxia yielded
superior functional outcomes at 90 days compared with the sham normobaric
hyperoxia, without raising safety concerns. Funding(s): Beijing
Municipal Education Commission, Beijing Municipal Finance Bureau, and
National Natural Science Foundation of China. Copyright © 2025
Elsevier Ltd

<23>
Accession Number
2037271818
Title
The risk of malnutrition as a predictor of arrhythmia recurrence after
catheter ablation in patients with paroxysmal non-valvular atrial
Fibrillation and heart failure with preserved ejection fraction.
Source
PLoS ONE. 20(1 January) (no pagination), 2025. Article Number: e0317721.
Date of Publication: 01 Jan 2025.
Author
Wang C.; Liu Q.; Xiao Y.; Zhou J.; Wu K.; Huang Y.; Zhang Z.; Liu S.; Lin
Q.
Institution
(Zhang, Wang, Liu, Xiao, Zhou, Wu, Huang, Zhang, Liu, Lin) Department of
Nutritional Sciences, The Second Xiangya Hospital, Central South
University, Hunan Province, Changsha City, China
Publisher
Public Library of Science
Abstract
Background Malnutrition presents a significant challenge in managing
patients with atrial fibrillation (AF) and heart failure with preserved
ejection fraction (HFpEF), yet its impact on AF recurrence after catheter
ablation in this population remains unclear. Methods We conducted a
retrospective analysis of 204 patients with paroxysmal non-valvular AF and
HFpEF who underwent radiofrequency or cryoballoon ablation. Risk of
malnutrition as assessed using three screening tools: the Controlling
Nutritional Status (CONUT) score, Prognostic Nutritional Index (PNI), and
Nutritional Risk Index (NRI)]. We examined the relationship between risk
of malnutrition and AF recurrence post-ablation. Results After a mean
follow-up period of 11.2 +/- 1.8 months, 43 patients (21.1%) experienced
AF recurrence. Despite being classified as overweight or obese based on
body mass index, many patients were at risk of malnutrition according to
the CONUT score, NRI, and PNI. Adjusted analyses showed that higher CONUT
scores (HR: 10.132; 95% CI: 2.545-40.336; P = 0.001), lower NRI (HR:
22.734; 95% CI: 6.399-80.776; P < 0.001), or lower PNI (HR: 9.469; 95% CI:
3.232-27.739; P < 0.001) were significantly associated with increased risk
of AF recurrence. Restricted cubic spline regression revealed an inverted
U-shaped relationship between the CONUT score and AF recurrence, and
L-shaped relationships for both NRI and PNI with AF recurrence.
Conclusions Systematic nutritional assessment is crucial in patients with
paroxysmal non-valvular AF and HFpEF. High CONUT scores, low NRI, or low
PNI serve as independent predictors for AF recurrence. Further large-scale
randomized controlled trials are required to validate these
findings. Copyright © 2025 Zhang et al. This is an open access
article distributed under the terms of the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original author and source are credited.

<24>
[Use Link to view the full text]
Accession Number
2035971103
Title
Effect of Exercise-Based Cardiac Rehabilitation on Patients With Chronic
Heart Failure After Transcatheter Aortic Valve Replacement: A Randomized
Controlled Trial.
Source
Journal of Cardiopulmonary Rehabilitation and Prevention. 45(1) (pp
51-56), 2025. Date of Publication: 01 Jan 2025.
Author
Song J.; Chen X.; Wang B.; Cheng Y.; Wang Y.
Institution
(Song, Chen, Wang, Cheng, Wang) Department of Cardiology, Xiamen
Cardiovascular Hospital of Xiamen University, School of Medicine, Xiamen
University, Fujian, Xiamen, China
Publisher
Lippincott Williams and Wilkins
Abstract
Purpose: The objective of this study was to assess the effect of
exercise-based cardiac rehabilitation (CR) with individualized exercise
prescription in patients with chronic heart failure (HF) undergoing
transcatheter aortic valve replacement (TAVR) in a randomized controlled
trial. Method(s): A total of 60 patients with chronic HF who received
TAVR treatment were randomly divided into the control group (n = 30) and
exercise training (ET) group (n = 30). The control group was treated with
conventional rehabilitation, and the ET group was given personalized
exercise-based CR based on a cardiopulmonary exercise test (CPX). The CPX
parameters, echocardiography, 6-minute walk test distance, and quality of
life were evaluated in the two groups. Result(s): All patients who
completed symptom-restricted CPX showed no complications. After the
12-week rehabilitation period, the levels of anaerobic threshold, peak
oxygen uptake, peak oxygen pulse, peak power, left ventricular ejection
fraction, and 6-minute walk test distance in the ET group were
significantly higher than those in the control group (P <.05). Scores on
the Minnesota Life with Heart Failure Questionnaire in the ET group were
lower than those in the control group (P <.05). Conclusion(s):
Exercise-based CR significantly improves cardiopulmonary function,
exercise tolerance, and quality of life in patients with chronic HF who
undergo TAVR. Copyright © 2025 Wolters Kluwer Health, Inc. All
rights reserved.

<25>
Accession Number
2035086891
Title
Transcatheter versus surgical aortic valve replacement: a meta-analysis of
comparative outcomes in low- and intermediate-risk patients with severe
aortic stenosis.
Source
Heart, Vessels and Transplantation. 8(4) (no pagination), 2024. Date of
Publication: 2024.
Author
Almuzainy S.; Hamodat O.S.; Nizar S.
Institution
(Almuzainy, Hamodat, Nizar) Faculty of Medicine, University of Sharjah,
Sharjah, United Arab Emirates
Publisher
Bishkek: Center for Scientific Research and Development of Education
Abstract
Objective: Aortic stenosis is the most common valvular heart disease. This
study aims to systematically analyze randomized clinical trials (RCTs)
data comparing transcatheter aortic valve replacement (TAVR) and surgical
aortic valve replacement (SAVR) in intermediate and low-risk patients with
severe symptomatic aortic stenosis. Method(s): We conducted a
meta-analysis of RCTs, performing an exhaustive search of major databases
to identify studies comparing TAVR and SAVR in low- to intermediate-risk
patients. We assessed mortality, stroke, length of hospital stay, and
other perioperative outcomes. Result(s): Nine RCTs with 8,884
patients (average age 77.76 years; 49.47% male) met the inclusion
criteria. Baseline characteristics were comparable between TAVR and SAVR
groups, with a low risk of bias. Pooled results showed a significant
reduction in mortality for TAVR compared to SAVR (RR 0.75, 95% CI
0.61-0.92, p = 0.007, I2 = 51%). TAVR significantly reduced
stroke incidence (RR 0.66, 95% CI 0.49-0.89, p = 0.007, I2 =
69%) and myocardial infarction (RR 0.60, 95% CI 0.37-0.96, p = 0.03,
I2 = 0%). No significant difference was found for prosthetic
valve endocarditis (RR 1.06, 95% CI 0.55-2.06, p = 0.85, I2 =
0%). Length of stay was significantly shorter for TAVR (MD -4.30 days, 95%
CI -5.03 to - 3.57, p = 0.00001, I2 = 93%). Conclusion(s):
TAVR is a viable option for intermediate and low-risk patients with severe
symptomatic aortic stenosis. Future research should focus on long-term
outcomes and TAVR device durability, especially in younger, lower-risk
populations. Copyright ©2024 Heart, Vessels and Transplantation.

<26>
Accession Number
2037330280
Title
Impella versus Non-Impella for Nonemergent High-Risk Percutaneous Coronary
Intervention.
Source
American Journal of Cardiology. (no pagination), 2025. Date of
Publication: 2025.
Author
Reddy P.; Merdler I.; Zhang C.; Cellamare M.; Ben-Dor I.; Bernardo N.;
Hashim H.; Satler L.; Rogers T.; Waksman R.
Institution
(Reddy, Merdler, Zhang, Cellamare, Ben-Dor, Bernardo, Hashim, Satler,
Rogers, Waksman) Section of Interventional Cardiology, MedStar Washington
Hospital Center, Washington, District of Columbia, United States
(Rogers) Cardiovascular Branch, Division of Intramural Research, National
Heart, Lung and Blood Institute, National Institutes of Health, Bethesda,
Maryland, United States
Publisher
Elsevier Inc.
Abstract
The benefit of mechanical circulatory support (MCS) with Impella (Abiomed,
Inc, Danvers, MA) for patients undergoing nonemergent, high-risk
percutaneous coronary intervention (HR-PCI) is unclear and currently the
subject of a large randomized clinical trial (RCT), PROTECT IV. While
contemporary registry data from PROTECT III demonstrated improvement of
outcomes with Impella when compared with historical data (PROTECT II),
there is lack of direct comparison to the HR-PCI cohort that did not
receive Impella support. We retrospectively identified patients from our
institution meeting PROTECT III inclusion criteria (left ventricular
ejection fraction [LVEF] <35% with unprotected left main or last remaining
vessel or LVEF <30% undergoing multivessel PCI), and compared this group
(NonIMP) to the published outcomes data from the PROTECT III registry
(IMP). Baseline differences were balanced using inverse propensity
weighting (IPW). The co-primary outcome was major adverse cardiac events
(MACE) in-hospital and at 90 days. Secondary outcomes included in-hospital
post-PCI complications. We identified 284 high-risk patients who did not
receive Impella support; 200 patients had 90-day event ascertainment and
were included in IPW analysis, with 504 patients in the IMP group. After
calibration, few residual differences remained; patients in the NonIMP
group were older (73.4 vs. 69.3, p <0.001) with higher prevalence of
coronary artery bypass grafting (65.0% vs. 13.7%, p <0.001). Unprotected
left main intervention was performed in 43% of patients in both groups.
The primary outcome was not different in-hospital (3.0% vs. 4.8%, p =
0.403), but lower in the NonIMP group at 90 days (7.5% vs. 13.8%, p =
0.033). Peri-procedural vascular complications, bleeding, and transfusion
rates were not different between groups. However, acute kidney injury
occurred more frequently in the NonIMP group (10.5% vs. 5.4%, p = 0.023).
Under identical HR-PCI inclusion criteria for Impella use in PROTECT III,
an institutional non-Impella supported HR-PCI cohort demonstrated similar
MACE in-hospital but lower MACE at 90 days. There was no signal for
peri-procedural harm with Impella use. These results do not support
routine usage of Impella for HR-PCI patients. Careful patient selection is
critical until a large RCT demonstrates benefits in a broad HR-PCI
population. Copyright © 2025

<27>
Accession Number
2037186026
Title
Continuous serratus anterior block for sternotomy analgesia after cardiac
surgery: a single-centre feasibility study.
Source
British Journal of Anaesthesia. (no pagination), 2025. Date of
Publication: 2025.
Author
Bailey J.G.; Hendy A.; Neira V.; Chedrawy E.; Uppal V.
Institution
(Bailey, Hendy, Neira, Uppal) Department of Anesthesia, Pain Management &
Perioperative Medicine, Dalhousie University, Halifax, NS, Canada
(Chedrawy) Division of Cardiac Surgery, Dalhousie University, Halifax, NS,
Canada
Publisher
Elsevier Ltd
Abstract
Background: Moderate-to-severe pain is common after cardiac surgery,
peaking during the first and second postoperative days. Several nerve
blocks for sternotomy have been described; however, the optimal location
for continuous catheters has not been established. This study assessed the
feasibility of a larger trial evaluating the efficacy of serratus anterior
plane (SAP) catheter analgesia for sternotomy pain. Method(s): This
double-blinded trial included patients undergoing cardiac surgery via
sternotomy. Bilateral SAP catheters were placed in all participants, and
randomised to ropivacaine or placebo. We assessed feasibility based on
predetermined endpoints: (1) average recruitment rate >4 per month; (2)
protocol adherence rate >90%; (3) primary outcome measurement rate >90%;
and (4) significant catheter-related adverse event rate <=2%. The quality
of recovery index (QoR-15) was compared using an independent t-test.
 Result(s): Of 52 participants randomised, feasibility data were
available for 50. A definitive study was deemed 'not feasible' in our
standalone centre owing to a low recruitment rate (2.4 per month) and a
high adverse event rate (pneumothorax rate 12%). There were no major
protocol deviations but minor deviations in 12% of participants. Pain,
opioid consumption, complications, and quality of recovery were not
different between groups. Long-term pain at 3 months was low in both
groups. Conclusion(s): A single-centre trial was deemed not feasible
for our setting. With limited data, the quality of recovery was not
different with ropivacaine dosing of bilateral SAP catheters for
sternotomy pain. Clinical trial registration: NCT04648774. Copyright
© 2025 The Author(s)

<28>
[Use Link to view the full text]
Accession Number
2033414620
Title
Organ Utilization From Donors Following Extracorporeal Cardiopulmonary
Resuscitation: A Systematic Review of Graft and Recipient Outcome.
Source
Transplantation. 109(2) (pp e109-e118), 2025. Date of Publication: 01 Feb
2025.
Author
Rajsic S.; Treml B.; Rugg C.; Innerhofer N.; Eckhardt C.; Breitkopf R.
Institution
(Rajsic, Treml, Rugg, Innerhofer, Eckhardt, Breitkopf) Department of
Anesthesiology and Intensive Care Medicine, Medical University Innsbruck,
Innsbruck, Austria
Publisher
Lippincott Williams and Wilkins
Abstract
Background. The global shortage of solid organs for transplantation is
exacerbated by high demand, resulting in organ deficits and steadily
growing waiting lists. Diverse strategies have been established to address
this issue and enhance organ availability, including the use of organs
from individuals who have undergone extracorporeal cardiopulmonary
resuscitation (eCPR). The main aim of this work was to examine the
outcomes for both graft and recipients of solid organ transplantations
sourced from donors who underwent eCPR. Methods. We performed a systematic
literature review using a combination of the terms related to
extracorporeal life support and organ donation. Using Preferred Reporting
Items for Systematic Reviews and Meta-analyses guidelines, PubMed and
Scopus databases were searched up to February 2024. Results. From 1764
considered publications, 13 studies comprising 130 donors and 322 organ
donations were finally analyzed. On average, included patients were 36 y
old, and the extracorporeal life support was used for 4 d. Kidneys were
the most often transplanted organs (68%; 220/322), followed by liver (22%;
72/322) and heart (5%; 15/322); with a very good short-term graft survival
rate (95% for kidneys, 92% for lungs, 88% for liver, and 73% for heart).
Four studies with 230 grafts reported functional outcomes at the 1-y
follow-up, with graft losses reported for 4 hearts (36%), 8 livers (17%),
and 7 kidneys (4%). Conclusions. Following eCPR, organs can be
successfully used with very high graft and recipient survival. In terms of
meeting demand, the use of organs from patients after eCPR might be a
suitable method for expanding the organ donation pool. Copyright
© 2024 Wolters Kluwer Health, Inc. All rights reserved.

<29>
Accession Number
2033057037
Title
RBT-1, a "preconditioning" agent, mitigates syndecan-1 shedding in
patients undergoing "on pump" cardiac surgery and following experimental
AKI.
Source
Physiological Reports. 13(3) (no pagination), 2025. Article Number:
e70218. Date of Publication: 01 Feb 2025.
Author
Johnson A.C.M.; Zager R.A.
Institution
(Johnson, Zager) Renibus Therapeutics, Southlake, TX, United States
(Zager) Fred Hutch Cancer Center, Seattle, WA, United States
(Zager) The University of Washington, Seattle, WA, United States
Publisher
American Physiological Society
Abstract
During systemic stress, syndecan-1 (SDC-1) shedding into plasma results,
implying endothelial damage. RBT-1, a "preconditioning" agent, has been
shown to mitigate postoperative complications following cardiac surgeries.
This study assessed whether RBT-1 preconditioning attenuated SDC-1
shedding in these patients, implying a vascular protective effect.
Patients (n, 112) were randomized to receive low-dose RBT-1, high-dose
RBT-1, or placebo 24-48 h prior to surgery. Plasma samples were obtained
before and 2 days postsurgery and assayed for SDC-1 (ELISA). To gain
further insights, male CD-1 mice were subjected to acute renal injuries,
and RBT-1's impact on plasma SDC-1 increases, vascular/aortic stress
responses (NGAL/KIM-1/IL-6 gene induction), and two vascular
cytoprotective pathways (Nrf2; ferritin) were assessed. Baseline plasma
SDC-1 levels did not differ between patient groups. The placebo group
developed an approximate 50% plasma SDC-1 (ng/mL) increase (p, 0.012).
Conversely, no significant SDC-1 increases were seen in the RBT-1
treatment groups. Experimental injury markedly increased plasma SDC-1
concentrations, and these were significantly blunted by RBT-1
preconditioning. RBT-1 also mitigated AKI-induced aortic NGAL/KIM-1/IL-6
mRNA increases, activated aortic Nrf2, and increased vascular ferritin
levels. RBT-1 preconditioning diminishes SDC-1 release and upregulates
vascular ferritin and Nrf2. Hence, RBT-1 preconditioning can confer select
vasoprotective effects. Copyright © 2025 The Author(s).
Physiological Reports published by Wiley Periodicals LLC on behalf of The
Physiological Society and the American Physiological Society.

<30>
Accession Number
2033036350
Title
Biomarkers predicting postoperative adverse outcomes in children with
congenital heart disease: a systematic review and meta-analysis.
Source
Frontiers in Pediatrics. 13 (no pagination), 2025. Article Number:
1508329. Date of Publication: 2025.
Author
Zhou S.; Liu L.; Jin X.; Dorikun D.; Ma S.
Institution
(Zhou, Jin, Dorikun, Ma) Pediatric Cardiothoracic Surgery, First
Affiliated Hospital of Xinjiang Medical University, Urumqi, China
(Zhou) College of Pediatrics, Xinjiang Medical University, Urumqi, China
(Liu) Hematology Department, First Affiliated Hospital of Xinjiang Medical
University, Urumqi, China
Publisher
Frontiers Media SA
Abstract
Objective: To statistically analyze biomarkers predicting postoperative
outcomes in children with congenital heart disease (CHD). Method(s):
PubMed, Embase, Cochrane Library, and Web of Science were performed to
search up to February 2024. The measured outcomes were biomarkers,
mortality, length of hospital stay, complication rates, and infection
rates. Adults with CHD were excluded. Standard deviation or odds ratio
(OR) with 95% confidence interval (95% CI) were extracted. A
random-effects model synthesized SMDs or ORs with 95% CIs. Sensitivity
analysis investigated heterogeneity, and Egger's test assessed publication
bias. Result(s): Seventeen eligible articles were included, the
biomarkers involved include serum lactate, NT-Pro BNP, PaO2, serum
creatinine, C1-INH activity, ST2, serum chloride concentration, GH,
glycemia, cTOI, NLR, serum albumin, and glucose levels, with 2,888
patients who underwent surgery(modified Norwood procedure, arterial switch
procedure, biventricular repair etc.). Serum lactate was higher in the
postoperative death group (SMD: 1.18, 95% CI: 0.59-1.77). Lower
postoperative N-terminal pro-B-type natriuretic peptide (NT-pro BNP)
levels were associated with lower mortality (OR: 0.23, 95% CI: 0.08-0.68)
and shorter mechanical ventilation time (OR: 0.40, 95% CI: 0.18-0.90).
Higher serum albumin levels were associated with longer hospital stays
(OR: 3.12, 95% CI: 1.66-5.84). Significant heterogeneity was found in
serum creatinine, B-type natriuretic peptide (BNP), serum lactate, and
NT-Pro BNP. Publication bias was detected in some studies.
 Conclusion(s): Serum lactate, NT-Pro BNP, and serum albumin are
reliable biomarkers for predicting adverse outcomes in children with CHD
after surgery. Systematic Review Registration: PROSPERO
[CRD42024512753]. Copyright 2025 Zhou, Liu, Jin, Dorikun and Ma.

<31>
Accession Number
2037180228
Title
Comparative Evaluation of Regain of Consciousness in
Dexmedetomidine-Propofol versus Ketamine-Propofol in the Pediatric Cardiac
Catheterization Procedure under Sedation using BIS Monitoring: A
Randomized Prospective Study.
Source
Annals of Cardiac Anaesthesia. 28(1) (pp 33-38), 2025. Date of
Publication: 2025.
Author
Banga P.; Negi S.L.; Mandal B.; Barwad P.; Saini K.; Gourav K.P.
Institution
(Banga, Negi, Mandal, Saini, Gourav) Department of Anaesthesia and
Intensive Care, Postgraduate Institute of Medical Education and Research,
Chandigarh, India
(Barwad) Department of Cardiology, Postgraduate Institute of Medical
Education and Research, Chandigarh, India
Publisher
Wolters Kluwer Medknow Publications
Abstract
Background: Congenital heart diseases (CHDs) are not rare and often
require an intervention at some point of time. Pediatric cardiac
catheterization, a minimally invasive procedure, is performed to diagnose
and to correct many cardiac abnormalities. Deep sedation with
spontaneously breathing patients is the preferred technique for pediatric
catheterization in the pediatric population. Therefore, the author aimed
to find the best combination of drugs for pediatric cardiac
catheterization procedures using dexmedetomidine-propofol (DP) and
ketamine-propofol (KP). Material(s) and Method(s): Cyanotic and
acyanotic CHD children, weighing 5-20 kg and undergoing sedation for
cardiac catheterization, were randomly assigned into two groups. DP group
children received a bolus intravenous (IV) propofol at 1 mg/kg body weight
followed by 1 mcg/kg dexmedetomidine over 10 minutes. KP group children
received a bolus IV propofol 1 mg/kg followed by ketamine 1 mg/kg over 10
minutes. For maintenance in the DP group, propofol infusion at 1.5 to 2
mg/kg/h and dexmedetomidine at 0.5 mcg/kg/h was started. In the KP group,
propofol infusion at 1.5 to 2 mg/kg/h and ketamine at 1 mg/kg/h was
started as maintenance. The bispectral index (BIS) was monitored
throughout the procedure, and the BIS value was maintained between 60 and
80. Propofol top of 1 mg/kg was administered when the BIS value became
more than 80 or when the child moved during the femoral vessel puncture or
when the child moved during the procedure. Result(s): The mean time
for regain of consciousness was faster (P < 0.005) in the KP group (11.02
+/- 11.98) compared to the DP group (21.62 +/- 18.68). BIS was monitored
throughout the procedure; BIS values were lower (P < 0.001) in the DP
group (60.0 +/- 11.1) as compared to the KP group (73.7 +/- 5.6). The
cumulative doses of propofol in the KP group and DP group were comparable.
Total fentanyl consumptions in the intraoperative period in the KP group
and DP group were comparable (P > 0.001). There was no difference in drug
side effects between the groups. Conclusion(s): The KP combination
had fast and early recovery compared to the DP combination in children who
underwent the cardiac catheterization procedure under sedation in children
undergoing cardiac catheterization procedures requiring
sedation. Copyright © 2025 Annals of Cardiac Anaesthesia.

<32>
Accession Number
2032965896
Title
Pre-operative subjective functional capacity and postoperative outcomes in
adult non-cardiac surgery: a systematic review and meta-analysis.
Source
Anaesthesia. (no pagination), 2025. Date of Publication: 2025.
Author
Takahashi K.; Chiba K.; Honda A.; Iizuka Y.; Yoshinaga K.; Deo A.S.;
Uchida T.
Institution
(Takahashi, Uchida) Department of Anaesthesiology, Institute of Science
Tokyo Hospital, Tokyo, Bunkyo, Japan
(Chiba, Honda, Iizuka) Department of Anaesthesiology and Critical Care
Medicine, Jichi Medical University Saitama Medical Centre, Saitama, Omiya,
Japan
(Yoshinaga) Department of Anaesthesiology and Critical Care Medicine,
Jichi Medical University, Tochigi, Shimotsuke, Japan
(Deo) Department of Anaesthesiology, NU Hospitals, Karnataka, Bengaluru,
India
Publisher
John Wiley and Sons Inc
Abstract
Introduction: Assessment of functional capacity is an essential part of
peri-operative risk stratification. Subjective functional capacity is
easier to examine than objective tests of patient fitness. However, the
association between subjective functional capacity and postoperative
outcomes has not been established. Method(s): Four databases were
searched for studies describing the associations between subjective
functional capacity and postoperative outcomes in adults undergoing
non-cardiac surgery. Meta-analysis was conducted among studies where
functional capacity was expressed in metabolic equivalents. The primary
outcome was postoperative major adverse cardiovascular events. Secondary
outcomes were mortality and postoperative overall complications. We
estimated the ORs of the outcomes in patients with poor functional
capacity (< 4 metabolic equivalents) as compared with those with good
functional capacity (>= 4 metabolic equivalents). Random-effects models
were used for the meta-analysis. Result(s): We identified 7835
abstracts. After screening and a full-text review, 23 studies were
selected. Evaluation methods of functional capacity included:
questionnaires (n = 7); specific questions (n = 6); and subjective
assessment by anaesthetists (n = 5). The probability of major
postoperative adverse cardiovascular events was significantly higher in
patients with poor functional capacity (OR 1.84, 95%CI 1.62-2.08) than in
those with good functional capacity. Patients with poor functional
capacity also had higher odds of mortality (OR 2.48, 95%CI 1.45-4.25) and
postoperative complications (OR 1.85, 95%CI 1.34-2.55).
 Discussion(s): Subjective functional capacity of < 4 metabolic
equivalents was associated with postoperative complications including
cardiovascular events and other serious outcomes. The results need to be
interpreted with caution due to the diverse measures used to assess
functional capacity. Copyright © 2025 Association of
Anaesthetists.

<33>
Accession Number
2033003097
Title
Osteopontin as a Biomarker for Coronary Artery Disease.
Source
Cells. 14(2) (no pagination), 2025. Article Number: 106. Date of
Publication: 01 Jan 2025.
Author
Layton G.R.; Antoun I.; Copperwheat A.; Khan Z.L.; Bhandari S.S.; Somani
R.; Ng A.; Zakkar M.
Institution
(Layton, Antoun, Bhandari, Somani, Ng, Zakkar) Department of
Cardiovascular Sciences, University of Leicester, Leicester, United
Kingdom
(Layton, Copperwheat, Zakkar) Department of Cardiac Surgery, University
Hospitals of Leicester NHS Trust, Leicester, United Kingdom
(Layton, Ng, Zakkar) Leicester British Heart Foundation Centre of Research
Excellence, Glenfield Hospital, Groby Road, Leicester, United Kingdom
(Antoun, Bhandari, Somani, Ng) Department of Cardiology, University
Hospitals of Leicester NHS Trust, Leicester, United Kingdom
(Khan) University of Lancaster, Lancaster, Bailrigg, United Kingdom
(Ng) National Institute of Health Research, Leicester, United Kingdom
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Osteopontin (OPN) is a sialylated phosphoprotein highly expressed in
atherosclerosis and upregulated in settings of both acute and chronic
inflammation. It is hypothesised that plasma levels of OPN may correlate
with the presence of coronary artery disease, "CAD". This offers potential
as a point-of-care testing biomarker for early diagnosis, disease
monitoring, and prognosis. This review evaluates the current literature on
the association between plasma OPN levels and coronary artery disease and
what is currently known to support its potential as a biomarker for future
practice. Electronic searches of MEDLINE and EMBASE databases were
undertaken from inception until July 2024. Thirty-three studies met the
inclusion criteria. All studies were observational, with gross
heterogeneity in methods used to analyse the association of plasma OPN
with clinical characteristics. They included case series, case-control,
cross-sectional, and cohort study designs. OPN has been linked to higher
cardiovascular risk and unfavourable cardiovascular outcomes. However, the
evidence regarding the direct assessment of CAD severity using tools like
the SYNTAX or TIMI scores, which focus on anatomical complexity and risk
factors, is less definitive. This suggests that OPN may be a more precise
reflection of the inflammatory processes and atherosclerotic activity
contributing to unfavourable outcomes rather than a direct indicator of
the anatomical severity of CAD itself. Consequently, OPN is increasingly
perceived as a marker of a poor prognosis rather than a tool for assessing
the severity of coronary artery lesions. Copyright © 2025 by the
authors.

<34>
Accession Number
2035571839
Title
Enoxaparin Versus Unfractionated Heparin in Acute Coronary Syndrome
Without St-Segment Elevation: A Systematic Review and Meta-Analysis.
Source
International Journal of Cardiovascular Sciences. 37 (no pagination),
2024. Article Number: e20240149. Date of Publication: 2024.
Author
Bertoli E.D.; Barros M.L.S.; Pasqualotto E.; Lima P.L.G.; Camerotte R.;
Nienkotter T.F.; Souza M.E.C.; Floriano I.T.; Kelly F.A.
Institution
(Bertoli, Nienkotter, Floriano) Universidade do Sul de Santa Catarina, SC,
Palhoca, Brazil
(Barros, Lima) Universidade Federal do Acre, AC, Rio Branco, Brazil
(Pasqualotto) Universidade Federal de Santa Catarina, SC, Florianopolis,
Brazil
(Camerotte) Universidade Federal do Rio de Janeiro, RJ, Rio de Janeiro,
Brazil
(Souza) Universidade de Pernambuco, PE, Recife, Brazil
(Kelly) Universidade Municipal de Sao Caetano do Sul, SP, Sao Caetano do
Sul, Brazil
Publisher
Sociedade Brasileira de Cardiologia
Abstract
Introduction: Enoxaparin is a known alternative to the use of
unfractionated heparin (UFH) in patients with acute coronary syndrome
(ACS). However, the evidence about which of these medications would have
the best benefit for these patients in 48 hours and 14 days is limited.
 Objective(s): Perform a meta-analysis of randomized controlled trials
(RCTs) comparing the safety of enoxaparin versus UFH in ACS without
ST-segment elevation (NSTE-ACS). Method(s): PubMed and Scopus
databases were searched for RCTs that compared enoxaparin versus UFH in
patients with NSTE-ACS. Risk ratios (RRs) for binary endpoints were
computed with 95% confidence intervals (CIs). Heterogeneity was examined
with I2 statistics. Statistical significance was defined as
P-value <0.05. Result(s): Five RCTs with 17,644 patients were
included, of whom 8,898 (50.4%) were treated with enoxaparin. There were
no significant differences between groups in myocardial infarction (MI) at
48h (RR 0.87; 95% CI 0.75-1.01) and 14 days (RR 0.91; 95% CI 0.79-1.05),
all-cause mortality at 48h (RR 1.02; 95% CI 0.62-1.69) and 14 days (RR
0.93; 95% CI 0.74-1.18), composite endpoint of death or MI at 48h (RR
0.87; 95% CI 0.75-1.00) and 14 days (RR 0.91; 95% CI 0.82-1.01), and
urgent revascularization at 48h (RR 0.40; 95% CI 0.08-1.95).
 Conclusion(s): These findings suggest that the use of enoxaparin in
the treatment of NSTE-ACS presents similar results to UFH. Copyright
© 2024, Sociedade Brasileira de Cardiologia. All rights reserved.

<35>
Accession Number
2033009615
Title
Maternal and neonatal outcomes in pregnant women undergoing cardiac
surgery: a systematic review and meta-analysis.
Source
Journal of Maternal-Fetal and Neonatal Medicine. 38(1) (no pagination),
2025. Article Number: 2451675. Date of Publication: 2025.
Author
Zhou C.; Zhou Y.; Xu Z.; Mei L.; Jin Y.
Institution
(Zhou, Zhou, Xu, Jin) Department of Gynaecology, Huzhou Maternity and
Child Health Care Hospital, Zhejiang Province, Huzhou City, China
(Mei) Department of Internal Medicine, Huzhou Maternity and Child Health
Care Hospital, Zhejiang Province, Huzhou City, China
Publisher
Taylor and Francis Ltd.
Abstract
Objective: Cardiac diseases that require surgical intervention present a
unique challenge during pregnancy and may affect both maternal and
neonatal outcomes. This systematic review and meta-analysis aimed to
evaluate maternal and neonatal outcomes in pregnant females undergoing
cardiac surgery. Method(s): A comprehensive manual and electronic
search was conducted in PubMed, EMBASE, Cochrane Library, and Web of
Sciences databases for studies published up to 31st May 2024.
Eligible studies were required to report maternal and neonatal outcomes of
women who underwent cardiac surgery during pregnancy. Random-effects
meta-analysis was conducted to estimate pooled maternal and neonatal
mortality proportions, and the results were presented as risk ratios (RR)
with 95% confidence intervals (CIs). Result(s): Seventeen studies met
the inclusion criteria, comprising a total sample size of 196 pregnant
women who underwent cardiac surgery. Cardiac surgery during pregnancy was
significantly (p < 0.001) linked to increased maternal and neonatal
mortality, with pooled RR of 4.9% (CI: 2.1%-7.6%) and 26.5% (CI:
19.7%-33.4%), respectively. Conclusion(s): This study highlights the
significant risks associated with cardiac surgery during pregnancy, such
as increased risk of maternal and neonatal mortality and higher incidence
of preterm labor. Our findings underscore the importance of specialized
care and multidisciplinary management for pregnant women with cardiac
conditions. Further research is warranted to identify strategies for risk
mitigation and improved outcomes in this vulnerable
population. Copyright © 2025 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis Group.

<36>
Accession Number
2032261248
Title
Effect of Ischemia Testing and Coronary Revascularization on Mortality and
Ventricular Tachycardia Recurrence in Patients With Monomorphic
Ventricular Tachycardia Without Acute Coronary Syndrome: A Meta-Analysis
and Systematic Review.
Source
Catheterization and Cardiovascular Interventions. 105(2) (pp 321-325),
2025. Date of Publication: 01 Feb 2025.
Author
Shah N.; Saraiya A.; Patel T.; Marchlinski F.E.; Pancholy S.
Institution
(Shah, Pancholy) The Wright Center for Graduate Medical Education,
Scranton, PA, United States
(Saraiya) Sidney Kimmel College of Medicine, Philadelphia, PA, United
States
(Patel) Apex Heart Institute, Ahmedabad, India
(Marchlinski) Perelman School of Medicine, University of Pennsylvania,
Philadelphia, PA, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Studies show mixed results regarding the effect of coronary
revascularization on mortality benefit and ventricular tachycardia (VT)
recurrence in patients with monomorphic VT without acute coronary syndrome
(ACS). This meta-analysis aimed to assess the effect of ischemia testing
and/or coronary revascularization on mortality and VT recurrence in a
pooled data set. Method(s): Databases including PubMed, Google
Scholar, and the Cochrane Library were searched from January 2000 to
December 2023 for studies reporting event data on mortality and VT
recurrence in patients without ACS who presented with monomorphic VT. Data
were pooled and analyzed using random effects meta-analysis.
 Result(s): The pooled sample consisted of a total of five studies,
with 1062 patients, of whom 433 underwent ischemia testing and/or coronary
revascularization and 629 did not. There was no statistically significant
difference in the mortality and VT recurrence in the patients who
underwent ischemia testing and/or revascularization versus those who did
not (mortality odds ratio [OR]: 0.98; [95% confidence interval (CI): 0.62
to 1.53]; p = 0.92; VT recurrence OR: 1.07; [95% CI: 0.51 to 2.26]; p =
0.86). No publication bias was detected by examination of the funnel plot,
Begg-Mazumdar's test (p = 0.80), and Egger's test (p = 0.91).
 Conclusion(s): In conclusion, in patients with sustained monomorphic
VT in the absence of ACS, ischemia testing and/or revascularization does
not lead to improved mortality or a decrease in the incidence of VT
recurrence. Copyright © 2024 Wiley Periodicals LLC.

<37>
Accession Number
2037231157
Title
Neurologic Complications Rate Following Aortic Manipulation after Off-Pump
Coronary Artery Bypass Grafting: A Meta-Analysis.
Source
Heart Surgery Forum. 28(1) (pp E096-E106), 2025. Date of Publication:
2025.
Author
Li L.; Yang J.; Li R.; Li G.; Wang X.; Feng S.; Guo H.
Institution
(Li, Yang, Li, Li, Wang, Feng, Guo) Cardiovascular Surgery, HanDan First
Hospital, Hebei, Handan, China
Publisher
Forum Multimedia Publishing LLC
Abstract
Background: Neurologic complications after coronary artery bypass grafting
continue to be among the most devastating complications. The goal of
coronary artery bypass grafting, which is performed utilizing off-pump
techniques on a beating heart, was to reduce this risk. The purpose of the
study was to assess the neurologic complications rate following aortic
manipulation after off-pump coronary artery bypass grafting.
 Method(s): Dichotomous random or fixed effect models generated the
odds ratio (OR) and mean difference (MD) with 95% confidence intervals
(CIs) based on the study of the meta-analysis data. 28 papers, with a
total of 823,972 patients, were available between 2002 and 2021 and were
comprised in this meta-analysis. Result(s): Aortic manipulation was
much less likely to cause a stroke in people with off-pump coronary artery
bypass grafting (OR, 0.58 95% CI, 0.44-0.77 p < 0.001) than non-aortic
manipulation. However, no significant difference was found between aortic
manipulation and non-aortic manipulation in all-cause mortality (OR, 0.84
95% CI, 0.69-1.02, p = 0.08), acute renal failure (OR, 0.86 95% CI,
0.69-1.08, p = 0.20), atrial fibrillation (OR, 0.67 95% CI, 0.21-2.15, p =
0.50), myocardial infarction (OR, 0.75 95% CI, 0.56-1.01, p = 0.06),
respiratory complications (OR, 0.64 95% CI, 0.40-1.03, p = 0.07),
reoperation for bleeding (OR, 0.89 95% CI, 0.57-1.38, p = 0.59), and
mediastinitis (OR, 0.77 95% CI, 0.46-1.28, p = 0.31) in subjects with
off-pump coronary artery bypass grafting. Conclusion(s): The present
evaluation showed that using aortic manipulation resulted in a
significantly lower rate of stroke occurence however, no significant
difference was found in all-cause mortality, acute renal failure, atrial
fibrillation, myocardial infarction, respiratory complications,
reoperation for bleeding, and mediastinitis compared to non-aortic
manipulation in subjects with off-pump coronary artery bypass grafting.
However, given that some comparisons comprised a small number of studies,
attention ought to be given to their values. Copyright: © 2025
The Author(s).

<38>
Accession Number
2032261371
Title
Diagnostic Performance of Quantitative Flow Ratio for the Assessment of
Non-Culprit Lesions in Myocardial Infarction (QFR-OUTSMART): Systematic
Review and Meta-Analysis.
Source
Catheterization and Cardiovascular Interventions. 105(2) (pp 308-320),
2025. Date of Publication: 01 Feb 2025.
Author
Salinas-Casanova J.A.; Jimenez-Franco V.A.; Jerjes-Sanchez C.;
Quintanilla-Gutierrez J.A.; De la Pena-Almaguer E.; Eguiluz-Hernandez D.;
Vences-Monroy S.; Joya-Harrison J.A.; Juarez-Gavino C.E.; Flores-Zertuche
M.M.; Ibarrola-Pena J.C.; Lira-Lozano D.; Molina-Aviles M.; Torre-Amione
G.
Institution
(Salinas-Casanova, Jimenez-Franco, Jerjes-Sanchez, Quintanilla-Gutierrez,
De la Pena-Almaguer, Joya-Harrison, Juarez-Gavino, Flores-Zertuche,
Ibarrola-Pena, Lira-Lozano, Molina-Aviles, Torre-Amione) Tecnologico de
Monterrey. Escuela de Medicina y Ciencias de la Salud, Nuevo Leon,
Monterrey, Mexico
(Salinas-Casanova, Jimenez-Franco, Jerjes-Sanchez, Quintanilla-Gutierrez,
De la Pena-Almaguer, Joya-Harrison, Juarez-Gavino, Flores-Zertuche,
Ibarrola-Pena, Lira-Lozano, Molina-Aviles, Torre-Amione) Instituto de
Cardiologia y Medicina Vascular, TecSalud, Escuela de Medicina y Ciencias
de la Salud, Tecnologico de Monterrey, Nuevo Leon, San Pedro Garza Garcia,
Mexico
(Eguiluz-Hernandez, Vences-Monroy) Tecnologico de Monterrey, Escuela de
Medicina y Ciencias de la Salud, Ciudad de Mexico, Mexico
Publisher
John Wiley and Sons Inc
Abstract
Background: Quantitative flow ratio (QFR) analysis is a simple and
non-invasive coronary physiological assessment method with evidence for
evaluating stable coronary artery disease with correlation to fractional
flow reserve (FFR). However, there is no evidence to recommend its use in
non-culprit lesions (NCLs) in myocardial infarction (MI). Method(s):
We performed a systematic review and meta-analysis using the PRISMA and
PROSPERO statements. The study's primary objective was to assess the
diagnostic accuracy of QFR in identifying functionally significant NCLs
after MI based on invasive FFR and non-hyperemic pressure ratios as
references. We obtained values of the area under the curve (AUC),
sensitivity, specificity, positive predictive value (PPV), and negative
predictive value (NPV). We performed a leave-one-out sensitivity analysis
for each study's impact on the overall effect. Result(s): We included
eight studies, with 713 patients and 920 vessels evaluated with QFR. The
overall AUC was 0.941 (I2 = 0.559, p < 0.002), with a
sensitivity of 87.3%, a specificity of 89.4%, a PPV of 86.6%, and an NPV
of 90.1%. Compared to FFR, we found an AUC of 0.957 (I2 =
0.331, p < 0.194), a sensitivity of 89.6%, a specificity of 89.8%, a PPV
of 88.3%, and an NPV of 91%. The sensitivity analysis showed a similar
diagnostic performance in both studies. Conclusion(s): QFR is
effective in analyzing NCLs with a significant diagnostic yield compared
to FFR, with an excellent AUC in MI patients. Performing prospective
multicenter studies to characterize this population and reproduce our
results is essential. Copyright © 2024 Wiley Periodicals LLC.

<39>
Accession Number
2032571909
Title
Clinical Outcomes Following Optical Coherence Tomographic Versus
Intravascular Ultrasound-Guided Percutaneous Coronary Intervention: A
Meta-Analysis of Randomized Controlled Trials.
Source
Catheterization and Cardiovascular Interventions. 105(2) (pp 532-540),
2025. Date of Publication: 01 Feb 2025.
Author
Dodoo S.N.; Ibrahim S.; Osman A.-F.; Balaji N.; Salih R.; Kilaru V.;
Ampadu D.K.; Dodoo A.S.; Egolum U.; Toleva O.; Ghasemzadeh N.; Ramadan R.;
Giugliano G.; Henry G.; Ibebuogu U.; Samady H.
Institution
(Dodoo, Egolum, Toleva, Ghasemzadeh, Ramadan, Giugliano, Henry, Samady)
Northeast Georgia Medical Center, Georgia Heart Institute, Gainesville,
GA, United States
(Ibrahim) Department of Internal Medicine, Piedmont Athens Regional
Medical Center, Athens, GA, United States
(Osman) Department of Cardiovascular Medicine, Creighton University School
of Medicine-Phoenix, Phoenix, AZ, United States
(Balaji, Salih, Kilaru) Department of Internal Medicine, Northeast Georgia
Medical Center, Gainesville, GA, United States
(Ampadu) Department of Medicine, University of Ghana Medical School,
Korle-Bu Teaching Hospital Slater Av, Accra, Ghana
(Dodoo) College of Pharmacy, Mercer University, Atlanta, GA, United States
(Ibebuogu) Department of Medicine, Division of Cardiovascular Medicine,
University of Tennessee Health Science Center, Memphis, TN, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Optical coherence tomography (OCT) and intravascular
ultrasound (IVUS) are adjunctive intracoronary imaging modalities used to
optimize coronary stent implantation. However, the impact of OCT versus
IVUS on clinical outcomes and periprocedural complications is unclear.
 Aim(s): To perform a meta-analysis of all vetted randomized
controlled trials comparing OCT-guided versus IVUS-guided percutaneous
coronary intervention. Method(s): We queried MEDLINE, Cochrane
Library, Scopus, and clinicalTrials.gov databases from their commencement
to February 2024 for all randomized controlled trials that compared
OCT-guided versus IVUS-guided percutaneous coronary interventions. The
primary endpoint was major adverse periprocedural events (MAPE), a
composite of stent thrombosis (ST), distal embolization (DE), and distal
edge dissection (DED) at 30 days. The secondary endpoints included ST, DE,
DED, major adverse cardiac events (MACE)-(a composite of cardiac death,
target vessel myocardial infarction TVMI], and target vessel
revascularization [TVR]), all-cause mortality, cardiac death, TVMI, TVR,
and nonfatal stroke at 1 year. The odds ratio (OR) with a 95% confidence
interval (CI) was analyzed using a random-effect model. Result(s):
Seven randomized controlled trials were included in the analysis, and 4446
patients were enrolled. OCT was associated with lower MAPE (OR: 0.65, CI:
0.47-0.91, p = 0.01) compared to IVUS. ST, DE, and DED were similar
between OCT and IVUS at 30 days. There were no significant differences in
MACE (OR: 0.86, CI: 0.64-1.16, p = 0.32), all-cause mortality (OR: 0.83,
CI: 0.42-1.66, p = 0.60), Cardiac death (OR:0.62, CI: 0.20-1.89, p =
0.40), TVMI (OR: 0.69, CI: 0.33-1.46, p = 0.33), TVR, (OR: 1.09, CI:
0.70-1.71, p = 0.70), and Nonfatal stroke (OR: 1.82, CI: 0.67-4.95, p =
0.24) 1 year following the index procedure. Conclusion(s): Optical
coherence tomographic-guided PCI was associated with lower MAPE, defined
as a composite of ST, DE, and DED, compared to IVUS-guided PCI at 30 days
of the index procedure. However, there was no difference in overall MACE,
TVMI, TVR, and nonfatal stroke at 1 year. Copyright © 2024 Wiley
Periodicals LLC.

<40>
Accession Number
2032208399
Title
Long-Term Clinical Outcomes of Biodegradable- Versus
Durable-Polymer-Coated Everolimus-Eluting Stents in Real-World
Post-Marketing Study.
Source
Catheterization and Cardiovascular Interventions. 105(2) (pp 301-307),
2025. Date of Publication: 01 Feb 2025.
Author
Abusnina W.; Case B.C.; Zhang C.; Chitturi K.R.; Sawant V.; Chaturvedi A.;
Haberman D.; Lupu L.; Sutton J.A.; Ali S.W.; Deksissa T.; Pokharel S.;
Ozturk S.T.; Margulies A.; Ben-Dor I.; Hashim H.D.; Satler L.F.;
Garcia-Garcia H.M.; Waksman R.
Institution
(Abusnina, Case, Zhang, Chitturi, Sawant, Chaturvedi, Haberman, Lupu,
Sutton, Ali, Deksissa, Pokharel, Ozturk, Margulies, Ben-Dor, Hashim,
Satler, Garcia-Garcia, Waksman) Section of Interventional Cardiology,
MedStar Washington Hospital Center, Washington, DC, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Long-term clinical data on biodegradable-polymer (BP)
drug-eluting stents (DES) are limited. The objective of this study was to
assess the long-term safety and efficacy of the BP-DES SYNERGY compared to
XIENCE V, a durable-polymer (DP)-DES. Method(s): We compared patients
treated with BP-DES or DP-DES at our center from 2008 to 2020. The primary
outcome was major adverse cardiac events (MACE), defined as the composite
of all-cause death, Q-wave myocardial infarction (MI), and target vessel
revascularization (TVR). Secondary endpoints were all-cause death, Q-wave
MI, target lesion revascularization (TLR), and stent thrombosis (ST).
 Result(s): A total of 4255 patients underwent propensity-score
matching, and 380 patients from each cohort were matched. There was no
significant difference between BP-DES and DP-DES concerning MACE (5-year
estimates: 21.6% vs. 26.6%, log-rank p = 0.259). Furthermore, there was no
difference in the TLR rate (5-year estimates: 7.3% vs. 8.6%, log-rank p =
0.781). All-cause death (5-year estimates: 13.6% vs. 12.9%, log-rank p =
0.72) and Q-wave MI (5-year estimates: 0.53% vs. 1.7%, log-rank p = 0.427)
were also comparable between the two groups. Of note, the rate of very
late ST was very low and similar between the groups (5-year estimates:
0.26% vs. 0.64%, log-rank p = 0.698). Conclusion(s): BP-DES and
DP-DES demonstrate similar safety and efficacy at 5-year follow-up. Both
can be used for the effective treatment of coronary artery
disease. Copyright © 2024 Wiley Periodicals LLC.

<41>
Accession Number
2032502877
Title
The Clinical Impact of Mitral Gradient Post Transcatheter Edge-To-Edge
Repair: A Systematic Review and Meta-Analysis.
Source
Catheterization and Cardiovascular Interventions. 105(2) (pp 413-425),
2025. Date of Publication: 01 Feb 2025.
Author
Alabdaljabar M.S.; Almiro A.; Khan J.; Gerberi D.J.; Murad M.H.; Thaden
J.J.; Rihal C.S.; Eleid M.F.
Institution
(Alabdaljabar) Department of Internal Medicine, Mayo Clinic, Rochester,
MN, United States
(Almiro, Khan) College of Medicine, Alfaisal University, Riyadh, Saudi
Arabia
(Gerberi) Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, United States
(Murad) Division of Public Health, Infectious Diseases, and Occupational
Medicine, Mayo Clinic, Rochester, MN, United States
(Thaden, Rihal, Eleid) Department of Cardiovascular Medicine, Mayo Clinic,
Rochester, MN, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Mitral transcatheter edge-to-edge repair (TEER) is a minimally
invasive therapy for severe mitral regurgitation (MR) in patients with
high surgical risk. TEER results in a tissue bridge that decreases mitral
valve area, potentially leading to elevated mean gradient. The clinical
impact of elevated gradient on outcomes is unclear. Method(s): This
systematic review and meta-analysis was based on a comprehensive search of
five databases. We included studies that evaluated post mitral TEER
gradient on one of the following outcomes: all-cause mortality, combined
endpoints, symptoms, hospitalizations, and mitral valve re-intervention.
Meta-analysis was conducted using the random-effects model.
 Result(s): Out of 6458 citations, 17 studies were included
(2017-2024) reporting on 7748 patients. There was significant
heterogeneity between studies related to the cutoff used to define
elevated gradient, etiology of MR, and outcomes. Elevated mitral gradient
post TEER (4, 4.5, 5 mmHg) was associated with worse combined endpoint (HR
= 1.35, 95% CI 1.07-1.71; I2 64%), but not all-cause mortality
(HR = 1.25, 95% CI 0.97-1.59; I2 45%) or risk of
hospitalization. For the combined endpoint, this association was mainly
significant in patients who had mitral gradient assessed using discharge
echocardiogram (HR = 1.39, 95% CI 1.07-1.81; I2 62%) for all
patients and for those with degenerative MR. Conclusion(s): Despite
the heterogeneity between studies, the current analysis suggests that
patients with elevated mitral gradient post TEER are at risk of worse
clinical outcomes, particularly in patients who had mitral gradient
assessed using discharge transthoracic echocardiogram. Copyright
© 2024 Wiley Periodicals LLC.

<42>
Accession Number
2037167260
Title
Pharmacological preventions and treatments for pericardial complications
after open heart surgeries.
Source
Heart. (no pagination), 2025. Article Number: heartjnl-2024-324805. Date
of Publication: 2025.
Author
Malektojari A.; Tahmasebipour R.; Fadaeihosein M.; Ghazizadeh S.; Ardali
F.; Haghighat B.; Keshavarz F.; Azari Y.Y.; Javdan F.; Shahsavari E.; Ersi
M.H.; Abbaszadeh S.; Al-Jafar R.; Dehghan A.; Pitre T.
Institution
(Malektojari, Ghazizadeh, Ardali, Shahsavari) Evidence Based Medicine
Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran,
Islamic Republic of
(Malektojari, Tahmasebipour, Ghazizadeh, Azari, Abbaszadeh) Cardiovascular
Research Center, Hormozgan University of Medical Sciences, Bandar Abbas,
Iran, Islamic Republic of
(Tahmasebipour, Fadaeihosein, Haghighat, Keshavarz, Azari, Javdan, Ersi)
Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar
Abbas, Iran, Islamic Republic of
(Al-Jafar, Dehghan) Department of Epidemiology and Biostatistics, School
of Public Health, Imperial College London, London, United Kingdom
(Al-Jafar) Data Services Sector, Lean Business Services, Riyadh, Saudi
Arabia
(Dehghan) MRC-PHE Centre for Environment and Health, School of Public
Health, Imperial College London, London, United Kingdom
(Pitre) Division of Respirology, Department of Medicine, University of
Toronto, Toronto, ON, Canada
Publisher
BMJ Publishing Group
Abstract
Background: Pericardial complications following cardiac surgery are common
and debilitating, significantly impacting patients' survival. We performed
this network meta-analysis to identify the most effective and safest
preventions and treatments for pericardial complications following cardiac
surgery. Method(s): We systematically searched PubMed/MEDLINE, EMBASE
and Cochrane CENTRAL from inception to 22 January 2024. Pairs of reviewers
screened eligible studies. They included randomised controlled trials that
enrolled adults undergoing major cardiac surgeries and reported
postpericardiotomy syndrome, pericardial effusion and pericarditis as
primary or secondary outcomes. We summarised the effects of interventions
using relative risks and corresponding 95% CIs. We performed a frequentist
random-effects network meta-analysis using the restricted maximum
likelihood estimator. Result(s): We included 39 trials that enrolled
a total of 6419 participants. Our network meta-analysis demonstrates
colchicine reduces the risk of postpericardiotomy syndrome (RR 0.53, 95%
CI 0.38 to 0.73). Beta-blockers probably prevent atrial fibrillation with
a large magnitude of effect (RR 0.4, 95% CI 0.20 to 0.81) and may prevent
postoperative pericarditis (RR 0.66, 95% CI 0.45 to 0.97) compared with
control. Fish oil (RR 0.28, 95% CI 0.09 to 0.90), non-steroidal
anti-inflammatory drugs (RR 0.37, 95% CI 0.23 to 0.59) and colchicine (RR
0.37, 95% CI 0.23 to 0.59) may reduce the risk of postoperative atrial
fibrillation. We found no evidence of a difference in the risk of pleural
effusion, all-cause mortality, serious adverse events or postoperative ICU
stay. Conclusion(s): The results of our study highly recommend
colchicine use to reduce the risk of the postpericardiotomy syndrome and
beta-blocker use to reduce postoperative atrial fibrillation.
Additionally, our study suggests that further research is needed to
investigate other interventions and to evaluate newly proposed
interventions in large, high-quality trials, as the current evidence for
some interventions is relatively weak. Copyright © Author(s) (or
their employer(s)) 2025. No commercial re-use. See rights and permissions.
Published by BMJ Group.

<43>
Accession Number
2032322415
Title
Transcatheter Aortic Valve Replacement in Patients With Severe Rheumatic
Aortic Stenosis: A Proportional Meta-Analysis.
Source
Catheterization and Cardiovascular Interventions. 105(2) (pp 345-348),
2025. Date of Publication: 01 Feb 2025.
Author
Ahsan M.J.; Ahmad S.; Ghumman G.M.; Dvalishvili M.; Malik S.A.; Islam
A.M.; Goldsweig A.M.
Institution
(Ahsan) Department of Cardiology, Baylor University Medical Center,
Dallas, TX, United States
(Ahmad, Malik, Goldsweig) Department of Cardiology, University of Nebraska
Medical Center, Omaha, NE, United States
(Ghumman) Department of Cardiology, St. Vincent Mercy Medical Center,
Toledo, OH, United States
(Dvalishvili) Department of Cardiology, East Carolina University,
Greenville, NC, United States
(Islam, Goldsweig) Department of Cardiology, Baystate Medical Center/UMass
Chan Medical School, Springfield, MA, United States
Publisher
John Wiley and Sons Inc

<44>
Accession Number
2032294140
Title
Effectiveness of virtual reality in cancer patients undergoing
chemotherapy. Systematic review.
Source
International Journal of Cancer. 156(7) (pp 1419-1428), 2025. Date of
Publication: 01 Apr 2025.
Author
Alvarado-Omenat J.J.; Llamas-Ramos R.; Garcia-Garcia D.; Correyero-Leon
M.; Fonseca-Sanchez E.; Llamas-Ramos I.
Institution
(Alvarado-Omenat) FisioSport Salamanca, S.L., Salamanca, Spain
(Llamas-Ramos, Llamas-Ramos) Department of Nursing and Physiotherapy,
Universidad de Salamanca, Salamanca, Spain
(Llamas-Ramos, Fonseca-Sanchez, Llamas-Ramos) Instituto de Investigacion
Biomedica de Salamanca (IBSAL), Salamanca, Spain
(Garcia-Garcia) Faculty of Health Sciences, University of Valladolid,
Soria, Spain
(Correyero-Leon) CRA La Villa, Valladolid, Spain
(Fonseca-Sanchez, Llamas-Ramos) University Hospital of Salamanca,
Salamanca, Spain
Publisher
John Wiley and Sons Inc
Abstract
Virtual reality is on the rise and is currently postulated as one of the
most innovative and promising techniques in the management of pain and
anxiety in cancer patients, in the face of painful processes or the stress
involved in chemotherapy treatment. The objective has been to find out the
effectiveness of virtual reality in patients undergoing chemotherapy.
Several literature reviews were conducted between November 2023 and
January 2024 in the Pubmed, Web of Science and PEDro databases. The
keywords "virtual reality," "cancer," "oncology," "exercise" and
"chemotherapy" were combined using the Boolean operator AND. 641
manuscripts were selected as potential manuscripts and after elimination
of duplicates and application of the inclusion and exclusion criteria, six
articles comprised the final review sample. Virtual reality has proven to
be an effective technique in reducing the anxiety, pain, asthenia and
stress suffered by patients diagnosed with cancer and chemotherapy
treatment. The distraction generated by this therapeutic modality, with a
wide range of scenarios, helps to reduce the painful perception and worry
of these procedures. However, there are no standard application guidelines
or application protocols that demonstrate the superiority of one technique
over another. Virtual reality could be a valid complementary tool in the
treatment of patients undergoing chemotherapy, showing positive results in
pain reduction, anxiety, stress or asthenia. More studies are needed, with
larger sample sizes and long-term follow-ups to establish treatment
protocols in relation to the frequency, intensity, duration and
periodicity of interventions with virtual reality. Copyright ©
2024 The Author(s). International Journal of Cancer published by John
Wiley & Sons Ltd on behalf of UICC.

<45>
Accession Number
2033078550
Title
Off-pump versus on-pump coronary artery bypass grafting in patients with
chronic obstructive pulmonary disease: a systematic review and
meta-analysis.
Source
General Thoracic and Cardiovascular Surgery. (no pagination), 2025.
Article Number: e14388. Date of Publication: 2025.
Author
Cappellaro A.P.; de Almeida L.F.C.; Pinto M.L.; Martins M.A.B.; Sousa
A.G.E.; Gadelha J.G.; Vieira A.C.P.; Rocha L.F.R.; Thet M.S.
Institution
(Cappellaro) Centro Universitario Mauricio de Nassau de Barreiras,
Barreiras, Brazil
(de Almeida, Rocha) Department of Surgery, Federal Fluminense University,
Niteroi, Brazil
(Pinto) Universidade Federal de Ciencias da Saude de Porto Alegre, Porto
Alegre, Brazil
(Martins) Universidade Federal de Ouro Preto, Ouro Preto, Brazil
(Sousa) Centro Universitario de Anapolis, Anapolis, Brazil
(Gadelha) Afya Faculdade de Ciencias Medicas da Paraiba, Joao Pessoa,
Brazil
(Vieira) Universidade Santo Amaro, Sao Paulo, Brazil
(Thet) Department of Surgery & Cancer, Imperial College London, South
Kensington, United Kingdom
Publisher
Springer
Abstract
Introduction: Off-pump coronary artery bypass graft surgery (OPCAB) has
been suggested as superior to on-pump coronary artery bypass graft surgery
(ONCAB) in certain high-risk subgroups, but its benefit in patients with
chronic obstructive pulmonary disease (COPD) remains controversial. This
meta-analysis aimed to evaluate OPCAB versus ONCAB outcomes in COPD
patients. Method(s): We followed PRISMA guidelines and searched
PubMed, Embase, and the Cochrane Library in August 2024 for studies
comparing OPCAB and ONCAB in COPD patients. Statistical analysis was
conducted using Review Manager 5.4.1 and Rstudio with a fixed or random
effects model. Result(s): Six studies with a total of 1,687 patients
were included, of which 1,062 (62.95%) underwent OPCAB. The mean patient
age was 63.6 years. OPCAB did not significantly affect all-cause mortality
compared to ONCAB (OR 1.14; 95% CI 0.65-1.99). There were no significant
differences in reintubation (OR 0.81; 95% CI 0.53-1.23), prolonged
ventilation (OR 0.54; 95% CI 0.24-1.22), post-operative atrial
fibrillation (OR 0.90; 95% CI 0.70-1.15), or ARDS (OR 0.43; 95% CI
0.14-1.33). However, ventilation time was significantly shorter in the
OPCAB group (MD - 5.30 h; 95% CI - 7.22 to - 3.38). Conclusion(s):
OPCAB is associated with reduced ventilation time in COPD patients though
it shows no significant difference in all-cause mortality or other
post-operative complications compared to ONCAB. Copyright © The
Author(s) 2025.

<46>
Accession Number
2037328674
Title
Role of Renin-Angiotensin System Inhibitors After Transcatheter Aortic
Valve Replacement: A Systematic Review and Meta-analysis.
Source
American Journal of Therapeutics. (no pagination), 2025. Article Number:
10.1097/MJT.0000000000001897. Date of Publication: 2025.
Author
Burhan M.; Noor S.; Ahmed M.; Shafiq S.; Ahmed R.; Shahid F.
Institution
(Burhan, Noor, Ahmed, Shafiq) Rawalpindi Medical University, Rawalpindi,
Pakistan
(Ahmed) Department of Cardiology, Royal Brompton Hospital, London, United
Kingdom
(Ahmed) National Heart and Lung Institute, Imperial College London,
London, United Kingdom
(Shahid) Department of Interventional Cardiology, Queen Elizabeth
Hospital, Birmingham, United Kingdom
Publisher
Lippincott Williams and Wilkins

<47>
Accession Number
2035615179
Title
Nitrogen single and multiple breath washout test and lung imaging to
detect treatment-related pulmonary toxicity in paediatric cancer patients
and survivors: a systematic review.
Source
European Respiratory Review. 34(175) (no pagination), 2025. Article
Number: 240178. Date of Publication: 01 Jan 2025.
Author
Schneider C.; Koenig C.; Zarkovic M.; Stranzinger E.; Rivero T.M.; Rossler
J.; Kuehni C.E.; Latzin P.; Schindera C.; Usemann J.
Institution
(Schneider, Koenig, Rossler) Division of Paediatric Haematology and
Oncology, Department of Paediatrics, Inselspital, Bern University
Hospital, University of Bern, Bern, Switzerland
(Schneider, Schindera, Usemann) University Children's Hospital Basel
(UKBB), Basel, Switzerland
(Schneider, Latzin, Usemann) Division of Paediatric Respiratory Medicine
and Allergology, Department of Paediatrics, Inselspital, Bern University
Hospital, University of Bern, Bern, Switzerland
(Schneider) Graduate School for Cellular and Biomedical Sciences,
University of Bern, Bern, Switzerland
(Zarkovic, Kuehni, Schindera) Institute of Social and Preventive Medicine,
University of Bern, Bern, Switzerland
(Zarkovic) Graduate School for Health Sciences, University of Bern, Bern,
Switzerland
(Stranzinger) Department of Diagnostic, Interventional and Paediatric
Radiology, Inselspital, Bern University Hospital, University of Bern,
Bern, Switzerland
(Rivero) Medical Library, University Library, University of Bern, Bern,
Switzerland
(Usemann) Division of Respiratory Medicine, University Children's Hospital
Zurich and Childhood Research Centre, Zurich, Switzerland
Publisher
European Respiratory Society
Abstract
Background Spirometry-based assessment of pulmonary function has
limitations in detecting pulmonary toxicity following cancer treatment
with chemotherapy, haematopoietic stem cell transplantation, radiotherapy
or thoracic surgery. Nitrogen single and multiple breath washout tests are
sensitive in assessing peripheral airway function, and lung imaging
detects structural abnormalities, but little is known about their use in
paediatric cancer patients and survivors. We aimed to 1) identify studies
using nitrogen single or multiple breath washout tests and/or lung imaging
to assess pulmonary toxicity in paediatric cancer patients and survivors,
and 2) describe reported abnormalities. Method We systematically searched
MEDLINE, Embase and the Cochrane Library for studies published in
1995-2023. Eligible studies included paediatric cancer patients and
survivors under 22 years of age receiving haematopoietic stem cell
transplantation, chemotherapy, radiotherapy and/or thoracic surgery who
underwent nitrogen single or multiple breath washout tests or lung imaging
for detecting pulmonary toxicity. Two independent reviewers identified the
studies, performed data extraction and assessed risk of bias. Results We
included 12 of 6544 publications. Three studies used nitrogen single or
multiple breath washout tests, seven conducted lung imaging using computed
tomography and two used both nitrogen single or multiple breath washout
tests and lung imaging. Abnormal test results for nitrogen single and
multiple breath washout tests and lung imaging were mainly reported
following haematopoietic stem cell transplantation (67%). All studies
performing lung imaging reported structural abnormalities. Study results
were heterogeneous due to varying patient and methodological
characteristics. Conclusion We identified a limited number of studies,
mainly after haematopoietic stem cell transplantation, reporting
functional and structural lung abnormalities in paediatric cancer patients
and survivors. Longitudinal studies with standardised assessments using
nitrogen single or multiple breath washout tests and lung imaging are
needed to improve our understanding of treatment-related pulmonary
toxicity. Copyright © The authors 2025.

<48>
Accession Number
2037313457
Title
Early diagnosis to avoid invasive treatment in cardiac migration of a
ventriculoperitoneal catheter: a qualitative systematic review and Weibull
analysis of case reports.
Source
Journal of Neurosurgery. 142(2) (pp 353-362), 2025. Date of Publication:
01 Feb 2025.
Author
Nakae T.; Hojo M.; Arakawa Y.
Institution
(Nakae, Arakawa) Department of Neurosurgery, Kyoto University Graduate
School of Medicine, Kyoto, Kyoto City, Japan
(Nakae, Hojo) Department of Neurosurgery, Shiga General Hospital, Shiga,
Moriyama, Japan
Publisher
American Association of Neurological Surgeons
Abstract
OBJECTIVE The migration of distal catheter after ventriculoperitoneal
shunt placement is a rare but significant complication. Especially in a
case of cardiac migration, open-heart surgery or catheter intervention may
be required. The authors encountered a case of cardiac migration that
fortunately could be treated by withdrawal. A systematic review of cardiac
migration was performed to clarify when and how migration was diagnosed
and why invasive treatments were required. Based on the collected cases, a
Weibull analysis of the latency until diagnosis was performed to examine
whether cardiac migration is caused by an initial factor and to compare
the result with the other migration sites such as gastrointestinal tract
or urinary tract. METHODS A qualitative systematic review was performed
according to the Preferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) guidelines. A database of case reports was created
by searching PubMed and Scopus with the keywords "ventriculoperitoneal AND
shunt AND migration"(last search date: April 2022). Whether the occurrence
rate of migration is constant over time was examined by fitting a Weibull
distribution. RESULTS A total of 339 articles of all migration sites were
identified. Among them, 36 articles reporting 38 cases of cardiac
migration were considered eligible. A total of 39 cases including the
authors' case were reviewed qualitatively. When classifying the cases by
their latency to diagnosis, the rates of pulmonary thrombosis and of
cardiac adhesion were higher in the delayed group (>= 1 year) than in the
early group (<= 1 month). The rate of open chest surgery was higher in the
delayed, intermediate, and early groups, in that order. In the Weibull
analysis, the shape parameter (beta) was less than 1, indicating that the
occurrence rate of cardiac migration was initially high, followed by a
decline. The finding supports the hypothesis that migration results from
an intraoperative vascular injury. Note that these findings are subject to
bias given that they are derived from case reports. CONCLUSIONS In light
of the previous reports, the latency until diagnosis of cardiac migration
was associated with the rate of thrombosis and adhesion, which resulted in
escalation to invasive treatment. Early diagnosis will prevent invasive
treatment because most cases are caused by initial factors, as the Weibull
analysis showed. Copyright © AANS 2025.

<49>
Accession Number
2037202344
Title
Safety and Efficacy of Tranexamic Acid in General Surgery.
Source
JAMA Surgery. (no pagination), 2025. Date of Publication: 2025.
Author
Park L.J.; Marcucci M.; Ofori S.N.; Borges F.K.; Nenshi R.; Kanstrup
C.T.B.; Rosen M.; Landoni G.; Lomivorotov V.; Painter T.W.; Xavier D.;
Martinez-Zapata M.J.; Szczeklik W.; Meyhoff C.S.; Chan M.T.V.; Simunovic
M.; Bogach J.; Serrano P.E.; Balasubramanian K.; Cadeddu M.; Yang I.; Kim
W.H.; Devereaux P.J.
Institution
(Park, Marcucci, Ofori, Borges, Nenshi, Balasubramanian, Devereaux)
Population Health Research Institute, Hamilton, ON, Canada
(Park, Nenshi, Simunovic, Bogach, Serrano, Cadeddu, Yang) Department of
Surgery, Division of General Surgery, McMaster University, Hamilton, ON,
Canada
(Park, Marcucci, Ofori, Borges, Serrano, Balasubramanian, Devereaux)
Department of Health Research Methods, Evidence & Impact, McMaster
University, Hamilton, ON, Canada
(Marcucci) Clinical Epidemiology and Research Centre (CERC), Humanitas
University, IRCCS Humanitas Research Hospital, Milan, Italy
(Ofori, Borges) Department of Medicine, McMaster University, Hamilton, ON,
Canada
(Kanstrup) Department of Surgery, Copenhagen University Hospital, North
Zealand, Hillerod, Denmark
(Rosen) Digestive Disease Institute, Cleveland Clinic Foundation,
Cleveland, OH, United States
(Landoni) Department of Anesthesia and Intensive Care, IRCCS San Raffaele
Scientific Institute, Milan, Italy
(Lomivorotov) Department of Anesthesiology and Intensive Care, E.
Meshalkin National Medical Research Center, Novosibirsk, Russian
Federation
(Painter) Royal Adelaide Hospital, Adelaide, SA, Australia
(Xavier) Division of Clinical Research & Training, St John's Research
Institute, Bengaluru, India
(Martinez-Zapata) Iberoamerican Cochrane Center, Institut de Recerca Sant
Pau, CIBER Epidemiologia y Salud Publica, Barcelona, Spain
(Szczeklik) Centre for Intensive Care and Perioperative Medicine,
Jagiellonian University Medical College, Krakow, Poland
(Meyhoff) Department of Anaesthesia and Intensive Care, Copenhagen
University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark
(Chan) The Chinese University of Hong Kong, Hong Kong
(Kim) Department of Anesthesiology and Pain Medicine, Seoul National
University College of Medicine, Seoul, South Korea
(Devereaux) Department of Medicine, Division of Cardiology, McMaster
University, Hamilton, ON, Canada
(Devereaux) World Health Research Trust, Hamilton, ON, Canada
Publisher
American Medical Association
Abstract
Importance: Perioperative bleeding is common in general surgery. The
POISE-3 (Perioperative Ischemic Evaluation-3) trial demonstrated efficacy
of prophylactic tranexamic acid (TXA) compared with placebo in preventing
major bleeding without increasing vascular outcomes in noncardiac surgery.
 Objective(s): To determine the safety and efficacy of prophylactic
TXA, specifically in general surgery. Design, Setting, and
Participant(s): Subgroup analyses were conducted that compared randomized
treatment with TXA vs placebo according to whether patients underwent
general surgery or nongeneral surgery in the POISE-3 blinded,
international, multicenter randomized clinical trial. Participants were 45
years or older, were undergoing noncardiac surgery, had increased
cardiovascular risk, and were expected to require at least an overnight
hospital admission after surgery. Among 26581 eligible patients
identified, 17046 were excluded, resulting in 9535 patients randomized to
the POISE-3 trial. Participants were enrolled from June 2018 through July
2021. The data were analyzed during December 2023. Intervention(s):
Prophylactic, 1-g bolus of intravenous TXA or placebo at the start and end
of surgery. Main Outcomes and Measures: The primary efficacy outcome
was a composite of life-threatening bleeding, major bleeding, or bleeding
into a critical organ. The primary safety outcome was a composite of
myocardial injury after noncardiac surgery, nonhemorrhagic stroke,
peripheral arterial thrombosis, or symptomatic proximal venous
thromboembolism at 30 days. Cox proportional hazards models were
conducted, incorporating tests of interaction. Result(s): Among 9535
POISE-3 participants, 3260 underwent a general surgery procedure. Mean age
was 68.6 (SD, 9.6) years, 1740 were male (53.4%), and 1520 were female
(46.6%). Among general surgery patients, 8.0% and 10.5% in the TXA and
placebo groups, respectively, had the primary efficacy outcome (hazard
ratio [HR], 0.74; 95% CI, 0.59-0.93; P =.01) and 11.9% and 12.5% in the
TXA and placebo groups, respectively, had the primary safety outcome (HR,
0.95; 95% CI, 0.78-1.16; P =.63). There was no significant interaction by
type of surgery (general surgery vs nongeneral surgery) on the primary
efficacy (P for interaction =.81) and safety (P for interaction =.37)
outcomes. Across subtypes of general surgery, TXA decreased the composite
bleeding outcome in hepatopancreaticobiliary surgery (HR, 0.55; 95% CI,
0.34-0.91 [n = 332]) and colorectal surgery (HR, 0.67; 95% CI, 0.45-0.98
[n = 940]). There was no significant interaction across subtypes of
general surgery (P for interaction =.68). Conclusions and Relevance:
In this study, TXA significantly reduced the risk of perioperative
bleeding without increasing cardiovascular risk in patients undergoing
general surgery procedures. Copyright © 2025 American Medical
Association. All rights reserved, including those for text and data
mining, AI training, and similar technologies.

<50>
Accession Number
2035578091
Title
Peculiarities of in-Stent Thrombosis and Restenosis in Coronary Arteries
Post-COVID-19: A Systematic Review of Clinical Cases and Case Series.
Source
Open Access Emergency Medicine. 17 (pp 15-30), 2025. Date of Publication:
2025.
Author
Pivina L.; Batenova G.; Omarov N.; Ygiyeva D.; Messova A.; Alibayeva G.;
Jamedinova U.; Kurumbayev R.; Pivin M.
Institution
(Pivina, Batenova, Omarov, Ygiyeva, Messova, Jamedinova, Kurumbayev)
Department of Emergency Medicine, Semey Medical University, Abay Region,
Semey, Kazakhstan
(Alibayeva) Semey Emergency Hospital, Abay Region, Semey, Kazakhstan
(Pivin) Nuclear Medicine Department, Center of Nuclear Medicine and
Oncology, Abay Region, Semey, Kazakhstan
Publisher
Dove Medical Press Ltd
Abstract
Background: One of the most serious complications of coronary artery
stenting is restenosis and in-stent thrombosis; their prevalence can reach
20-25%. Stent thrombosis can be acute (up to 24 hours), subacute (24 hours
to 30 days), late (30 days to 1 year), and very late (> 1 year after
previous stenting). In the patients with COVID-19 in intensive care units,
the proportion of those with elevated troponin levels reached 25%.
 Objective(s): Evaluation of the association between COVID-19 and the
development of in-stent thrombosis and restenosis of the coronary arteries
based on the analysis of clinical cases and case series. Material(s)
and Method(s): We searched the PubMed and Scopus databases for relevant
case reports and case series of stent restenosis and in-stent thrombosis
associated with coronavirus infection (CVI) published between 2020 and the
present. Thirty-eight full-text publications were screened and manually
checked for analysis. We found 10 publications describing cases of
thrombosis and restenosis of stents associated with coronavirus infection,
of which only 2 were case series. In total, we analyzed 22 cases.
 Result(s): In the structure of in-stent restenosis and thrombosis,
59.1% were very late, 9.1% were late; 18.2% were considered subacute
events, and 13.6% were acute events. All cases were angiographically
confirmed. The main location of restenosis or thrombosis was the left
coronary artery (LAD) (51.1%), thrombosis of the right coronary artery
(RCA) occurred in 27.3%, and location in circumflex artery was in 22.7%.
All patients had COVID-19 confirmed by a PCR test or the presence of
immunoglobulins G and M. In fourteen patients (54.5%), an X-ray
examination showed the presence of bilateral polysegmental infiltration.
 Conclusion(s): Analysis of publications demonstrates the association
between restenosis and in-stent thrombosis in patients with coronary
arteries disease (CAD) and coronavirus infection. Copyright ©
2025 Pivina et al.

<51>
Accession Number
2037204768
Title
Macrophage polarization in cardiac transplantation: Insights into immune
modulation and therapeutic approaches.
Source
Biocell. 49(1) (pp 61-78), 2025. Date of Publication: 2025.
Author
Jiang J.; Jia B.; Wang C.; Fang C.; Li Y.; Ling G.; Zheng B.; Luo C.
Institution
(Jiang, Fang, Li, Ling, Zheng, Luo) Department of Cardiovascular Surgery,
The First Affiliated Hospital of Guangxi Medical University, Nanning,
China
(Jiang) The First Clinical Medical College of Guangxi Medical University,
Nanning, China
(Jia, Wang) Department of Cardiovascular Surgery, Beijing Anzhen Hospital
of Capital Medical University, Beijing, China
Publisher
Tech Science Press
Abstract
The role and regulatory mechanisms of macrophage polarization in cardiac
transplantation have gained significant attention. Macrophages can
polarize into either the M1 (pro-inflammatory) or M2 (anti-inflammatory)
phenotype in response to environmental cues. M1 macrophages facilitate
transplant rejection by releasing inflammatory mediators and activating T
cells, whereas M2 macrophages support graft survival by secreting
anti-inflammatory factors and promoting tissue repair. Mitochondrial
quality control regulation plays a crucial role in macrophage
polarization, which may influence graft survival and immune responses.
This review provides an overview of the current understanding of
mitochondrial quality control-regulated macrophage polarization in cardiac
transplantation, its effects on graft outcomes, and potential therapeutic
strategies to modulate this process to enhance transplant success rates.
The review was conducted by systematically analyzing recent studies and
integrating findings from key research articles to synthesize a
comprehensive understanding of this emerging field. Copyright ©
2025 The Authors.

<52>
Accession Number
2037272949
Title
Treatment of Pleural Mesothelioma: ASCO Guideline Update.
Source
Journal of Clinical Oncology. (no pagination), 2025. Article Number:
JCO-24-02425. Date of Publication: 2025.
Author
Kindler H.L.; Ismaila N.; Bazhenova L.; Chu Q.; Churpek J.E.; Dagogo-Jack
I.; Bryan D.S.; Drazer M.W.; Forde P.; Husain A.N.; Sauter J.L.; Rusch V.;
Bradbury P.A.; Cho B.C.J.; De Perrot M.; Ghafoor A.; Graham D.L.; Khorshid
O.; Lebensohn A.; White J.; Hassan R.
Institution
(Kindler, Bryan, Drazer, Husain) University of Chicago Medicine, Chicago,
IL, United States
(Ismaila) American Society of Clinical Oncology, Alexandria, VA, United
States
(Bazhenova) University of California San Diego Moores Cancer Center, La
Jolla, CA, United States
(Chu) Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
(Churpek) University of Wisconsin-Madison and Carbone Cancer Center,
Madison, WI, United States
(Dagogo-Jack) Massachusetts General Hospital Cancer Center, Boston, MA,
United States
(Forde) Johns Hopkins University, Baltimore, MD, United States
(Sauter, Rusch) Memorial Sloan Kettering Cancer Center, New York, NY,
United States
(Bradbury, Cho) Princess Margaret Cancer Centre, Toronto, ON, Canada
(De Perrot) Toronto General Hospital, Toronto, ON, Canada
(Ghafoor, Lebensohn, Hassan) Center for Cancer Research, National Cancer
Institute, Bethesda, MD, United States
(Graham) Levine Cancer Institute, Charlotte, NC, United States
(Khorshid) National Cancer Institute, Cairo University, Cairo, Egypt
(White) Mesothelioma Foundation, Washington, DC, United States
Publisher
Lippincott Williams and Wilkins
Abstract
ASCO Guidelines provide recommendations with comprehensive review and
analyses of the relevant literature for each recommendation, following the
guideline development process as outlined in the ASCO Guidelines
Methodology Manual. ASCO Guidelines follow the ASCO Conflict of Interest
Policy for Clinical Practice Guidelines. Clinical Practice Guidelines and
other guidance ("Guidance") provided by ASCO is not a comprehensive or
definitive guide to treatment options. It is intended for voluntary use by
clinicians and should be used in conjunction with independent professional
judgment. Guidance may not be applicable to all patients, interventions,
diseases or stages of diseases. Guidance is based on review and analysis
of relevant literature and is not intended as a statement of the standard
of care. ASCO does not endorse third-party drugs, devices, services, or
therapies and assumes no responsibility for any harm arising from or
related to the use of this information. See complete disclaimer in
Appendix 1 and 2 (online only) for more. PURPOSE To provide evidence-based
recommendations to practicing physicians and others on the management of
pleural mesothelioma (PM). METHOD(S): ASCO convened an Expert Panel
of medical oncology, thoracic surgery, radiation oncology, pathology,
cancer genetics, and advocacy experts to conduct an updated literature
search, which included systematic reviews, meta-analyses, randomized
controlled trials, and prospective and retrospective comparative
observational studies published from 2016 through 2024. Outcomes of
interest included survival, disease-free or recurrence-free survival, and
quality of life. Expert Panel members used available evidence and informal
consensus to develop evidence-based guideline recommendations. RESULTS The
literature search identified 110 additional relevant studies to inform the
evidence base for this guideline. RECOMMENDATIONS Evidence-based
recommendations were developed for surgical cytoreduction, immunotherapy,
chemotherapy, pathology, and germline testing in patients with
PM. Copyright © 2025 by American Society of Clinical Oncology.

<53>
Accession Number
2037346925
Title
Current evidence and indications for left atrial appendage closure.
Source
Journal of Cardiology. (no pagination), 2025. Date of Publication: 2025.
Author
Shinohara M.; Saji M.; Koike H.; Ohara H.; Enomoto Y.; Nakanishi R.;
Fujino T.; Ikeda T.
Institution
(Shinohara) Helmsley Electrophysiology Center, Department of Cardiology,
Icahn School of Medicine at Mount Sinai, New York, NY, United States
(Shinohara, Saji, Koike, Ohara, Nakanishi, Fujino, Ikeda) Division of
Cardiovascular Medicine, Department of Internal Medicine, Toho University
Faculty of Medicine, Tokyo, Japan
(Enomoto) Division of Cardiovascular Medicine, Toho University Ohashi
Medical Center, Tokyo, Japan
(Enomoto) Division of Cardiology, National Center for Global Health and
Medicine Hospital, Tokyo, Japan
Publisher
Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)
Abstract
Atrial fibrillation (AF) is the most common arrhythmia worldwide and its
prevalence increases with age. The main and most severe complication of AF
is ischemic stroke, yet an estimated 50 % of eligible patients cannot
tolerate or are contraindicated to receive oral anticoagulation (OAC). In
patients with AF, the left atrial appendage (LAA) is the main source of
thrombus formation. Percutaneous LAA closure (LAAC) has emerged over the
past two decades as a valuable alternative to OAC for reducing the risk of
strokes and systemic embolisms in patients with AF who cannot tolerate
long-term OAC. With newer generation devices such as the Watchman (Boston
Scientific, Natick, MA, USA) and Amulet (Abbott, Abbott Park, IL, USA)
gaining approval from the US Food and Drug Administration in recent years,
the safety and efficacy of LAAC in specific populations intolerant to OAC
have increased and more patients are being treated. This systematic review
provides the indications for LAAC and the evidence for evaluating the use
of the currently available device therapies. We also examine the current
unsolved problems with patient selection and postprocedural antithrombotic
regimens. Copyright © 2025 Elsevier Ltd

<54>
Accession Number
2037273694
Title
Economic Outcomes With Precision Diagnostic Testing Versus Usual Testing
in Stable Chest Pain: Results From the PRECISE Randomized Trial.
Source
Circulation: Cardiovascular Quality and Outcomes. (no pagination), 2025.
Article Number: 10.1161/CIRCOUTCOMES.123.011008. Date of Publication:
2025.
Author
Chew D.S.; Mark D.B.; Li Y.; Nanna M.G.; Kelsey M.D.; Daniels M.R.;
Davidson-Ray L.; Baloch K.N.; Rogers C.; Patel M.R.; Anstrom K.J.; Curzen
N.; Vemulapalli S.; Douglas P.S.
Institution
(Chew) Libin Cardiovascular Institute and O'Brien Institute for Public
Health, University of Calgary, Calgary, Canada
(Mark, Li, Kelsey, Daniels, Davidson-Ray, Baloch, Patel, Vemulapalli,
Douglas) Duke Clinical Research Institute, Duke University, Durham, NC,
United States
(Mark, Kelsey, Patel, Vemulapalli, Douglas) Division of Cardiology, Duke
University Medical Center, Durham, NC, United States
(Nanna) Section of Cardiovascular Medicine, Yale University School of
Medicine, New Haven, CT, United States
(Rogers) HeartFlow, Inc, Mountain View, CA, United States
(Anstrom) Gillings School of Global Public Health, University of North
Carolina, Chapel Hill, United States
(Curzen) Faculty of Medicine, University of Southampton, Cardiothoracic
Unit, University Hospital Southampton, United Kingdom
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: The PRECISE (Prospective Randomized Trial of the Optimal
Evaluation of Cardiac Symptoms and Revascularization) demonstrated that a
precision diagnostic strategy reduced the primary composite of death,
nonfatal myocardial infarction, or catheterization without obstructive
coronary artery disease by 65% in patients with nonacute chest pain
compared with usual testing. Medical cost was a prespecified secondary end
point. METHOD(S): PRECISE randomized 2103 patients between December
2018 and May 2021 to usual testing or a precision strategy that used
deferred testing for the lowest risk patients (20%) and coronary computed
tomographic angiography with selective computed tomography-derived
fractional flow reserve for the remainder. Resource use consumption data
were collected from all study participants and hospital cost data from US
participants (n=1125) to estimate total medical costs. The primary and
secondary economic outcomes were total costs at 12 months and at 45 days,
respectively, from the US health care system perspective. The mean cost
differences between the 2 strategies were reported by intention-to-treat.
 RESULT(S): At 45 days, total costs were similar between the precision
strategy and usual testing (mean difference, $182 [95% CI, -$555 to
$661]). By 12 months, percutaneous coronary intervention and coronary
artery bypass surgery had been performed in 7.2% and 2.0% of precision
strategy patients and 3.5% and 1.7% of usual testing patients,
respectively. At 1 year, precision strategy costs were $5299 versus $4821
for usual testing (mean difference, $478 [95% CI, -$889 to $1437];
P=0.43). Precision care decreased mean per-patient diagnostic cost by 27%
and increased mean per-patient revascularization costs by 67%.
 CONCLUSION(S): In the PRECISE trial, the precision strategy, a
risk-based approach endorsed by current clinical practice guidelines,
improved the clinical efficiency of testing and had similar costs to usual
testing at 45 days and a nonsignificant $478 cost difference at 1
year. Copyright © 2025 The Authors.

<55>
Accession Number
2037346943
Title
Efficacy of surgical ablation and left atrial appendage occlusion in
patients with AF undergoing coronary artery bypass grafting: A network
meta-analysis.
Source
Journal of Cardiology. (no pagination), 2025. Date of Publication: 2025.
Author
Awad A.K.; Elbahloul M.A.; Gamal A.; Attia A.N.; Hamed S.M.; Elsekhary
A.I.; Sa M.P.
Institution
(Awad) Faculty of Medicine, Ain-Shams University, Cairo, Egypt
(Awad) Department of Cardiothoracic Surgery, Ain-Shams University
Hospitals, Cairo, Egypt
(Elbahloul) Faculty of Medicine, Kafr El-Shaikh University, Kafr
El-Shaikh, Egypt
(Gamal) Clinical Pharmacy Department, Faculty of Pharmacy, Deraya
University, Minia, Egypt
(Attia, Elsekhary) Kasr Alainy School of Medicine, Cairo University,
Cairo, Egypt
(Hamed) Faculty of Medicine, Mansura University, Dakahlia, Egypt
(Sa) Division of Cardiac Surgery, Massachusetts General Hospital, Harvard
Medical School, Boston, MA, United States
Publisher
Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)
Abstract
Background: Atrial fibrillation (AF) is a prevalent cardiac arrhythmia
that greatly elevates the risk of stroke. This risk increases both during
and after cardiac procedures, such as coronary artery bypass grafting
(CABG). There is an increasing interest in non-pharmacological treatments
such as left atrial appendage occlusion (LAAO) and surgical ablation,
intending to enhance both immediate and long-term postoperative results.
 Objective(s): To investigate the efficacy of surgical ablation (SA),
LAAO, or both in patients with AF undergoing CABG. Method(s): We
searched four electronic databases: PubMed, Scopus, Cochrane Library, and
WOS. We analyzed data using R language and "netmeta" and "netrank"
packages of meta-insight software. Pooled outcomes were reported as mean
difference or risk ratio (RR) with 95 % confidence interval (CI) in a
random effect method. Result(s): A total of 16 studies were included
with 594,312 patients included. The 30-day mortality showed a
non-statistically significant difference between CABG-LAAO compared to
CABG alone and CABG-SA with RR of 1.70 (95%CI 0.38-7.61) and 0.62 (95%CI
0.10-3.94). However, compared to CABG alone, CABG-SA + LAAO, CABG-LAAO,
and CABG-SA had significantly lower risk of long-term mortality with RR
0.75 (95%CI 0.57-0.98), 0.78 (95%CI 0.65-0.94), and 0.73 (95%CI
0.61-0.88), respectively. CABG-SA + LAAO, CABG-LAAO, and CABG-SA reduced
the risk of short-term stroke compared to CABG alone with RR of 0.73
(95%CI 0.43-1.24), 0.93 (95%CI 0.78-1.11), and 1.01 (95%CI 0.75-1.36),
respectively. Moreover, only CABG-SA + LAAO and CABG-LAAO showed a
statistically significant reduction in long term stroke and
hospitalization due to heart failure while CABG-SA showed no statistically
significant difference. Furthermore, there was no statistically
significant difference between our interventions in terms of 30-day
rehospitalization, intra-aortic balloon pump support, and risk of
hemorrhage. Conclusion(s): Among patients with AF undergoing CABG,
whether undergoing SA alone or LAAO alone or both showed significant
clinical outcomes such as reduced risk of both short- and long-term
mortality and short-term stroke. Copyright © 2025 Elsevier Ltd

<56>
Accession Number
2033097075
Title
Effect of aspirin dosage on oxidative stress and platelet reactivity in
patients undergoing coronary artery bypass grafting (APRICOT): randomized
controlled trial.
Source
Platelets. 36(1) (no pagination), 2025. Article Number: 2457415. Date of
Publication: 2025.
Author
Gasecka A.; Kaczorowski R.; Pomykala K.; Kucharski T.; Gajewska M.; Siwik
D.; Karon K.; Malyszko M.; Hunia J.; Zimodro J.M.; Kowalczyk P.;
Zagrocka-Stendel O.; Dutkiewicz M.; Koziak K.; Eyileten C.; Postula M.;
Wondolkowski M.; Grabowski M.; Kusmierczyk M.; Wilimski R.
Institution
(Gasecka, Kaczorowski, Pomykala, Kucharski, Gajewska, Hunia, Zimodro,
Grabowski) Department of Cardiology, Medical University of Warsaw, Warsaw,
Poland
(Siwik) Department of Psychiatry, Medical University of Warsaw, Warsaw,
Poland
(Karon) Department of Internal Medicine with the Diabetology, Metabolic
Disorders Unit and the Endocrine Diagnostics Unit, Bielanski Hospital,
Warsaw, Poland
(Malyszko) Department of Gastroenterology and Internal Medicine, Medical
University of Warsaw, Warsaw, Poland
(Kowalczyk) Department of Animal Nutrition, The Kielanowski Institute of
Animal Physiology and Nutrition, Polish Academy of Sciences, Jablonna,
Poland
(Zagrocka-Stendel, Dutkiewicz, Koziak) Department of Immunology,
Biochemistry and Nutrition, Medical University of Warsaw, Warsaw, Poland
(Eyileten, Postula) Department of Experimental and Clinical Pharmacology,
Medical University of Warsaw, Warsaw, Poland
(Eyileten, Postula) Center for Preclinical Research and Technology,
Medical University of Warsaw, Warsaw, Poland
(Wondolkowski, Kusmierczyk, Wilimski) Department of Cardio-Thoracic
Surgery and Transplantology, Medical University of Warsaw, Warsaw, Poland
Publisher
Taylor and Francis Ltd.
Abstract
Coronary artery bypass grafting (CABG) triggers oxidative stress and
platelet activation. High acetylsalicylic acid (ASA) dose might mitigate
the transient proinflammatory state. We compared the effect of three ASA
dosages on post-CABG platelet reactivity, oxidative stress, and serum CD39
and CD73 levels. Thirty-six consecutive patients undergoing elective
off-pump CABG, pre-treated with ASA 1 x 75 mg for >=7 days, were
randomized to continue the prior treatment regimen, switch to ASA 1 x 150
mg, or ASA 2 x 75 mg. Blood was collected on admission, 7 days, 1 month,
and 3 months after CABG. Platelet reactivity was assessed using impedance
aggregometry. Platelet oxidative stress was measured as platelet
mitochondria extracellular oxygen consumption rate and oxidatively damaged
whole-blood DNA cleavage. Serum CD39 and CD73 levels were determined using
ELISA. Platelet reactivity and oxidative stress parameters were comparable
in all groups. Patients treated with ASA 2 x 75 mg had higher CD39 levels
at 7 days and 1 month (p =.049, p =.033), compared to the control group.
ASA 2 x 75 mg was associated a beneficial effect on serum CD39 levels
after off-pump CABG, without a significant effect on oxidative stress
parameters. Copyright © 2025 The Author(s). Published with
license by Taylor & Francis Group, LLC.

<57>
Accession Number
646413764
Title
The effect of preoperative deep breathing exercise with incentive
spirometer initiated in the preoperative period on respiratory parameters
and complications in patients underwent open heart surgery: a randomized
controlled trial.
Source
BMC anesthesiology. 25(1) (pp 36), 2025. Date of Publication: 24 Jan 2025.
Author
Oner Cengiz H.; Ulusan Ozkan Z.; Gani E.
Institution
(Oner Cengiz) Ankara University Faculty of Nursing, Department of Nursing,
Department of Surgical Diseases Nursing, Ankara, Turkey
(Ulusan Ozkan, Gani) Ankara Training and Research Hospital, Cardiovascular
Surgery Clinic, Ankara, Turkey
Abstract
BACKGROUND: Incentive spirometer is used in lung expansion therapy to
maintain alveolar patency and improve pulmonary volumes in postoperative
cardiac surgical patients. Deep breathing exercises with an incentive
spirometer significantly reduce the development of postoperative pulmonary
complications after open-heart cardiac surgery. AIM: To determine the
effect of deep breathing exercises with an incentive spirometer initiated
in the preoperative period on respiratory parameters and complications in
patients who underwent open-heart surgery. METHOD(S): This randomized
controlled study was conducted with a total of 66 participants. The
participants were randomized into a deep breathing group (n = 32) and a
control group (n = 34). The control group received hospital routine
physiotherapy, and the deep breathing group started to perform deep
breathing exercises with an incentive spirometer in the preoperative
period. Data were collected with the Sociodemographic and Medical Data
Form and Patient Follow-up Form (respiratory rate, oxygen saturation
(SpO2) level, arterial blood gas parameters and posteroanterior chest
X-ray were monitored with this form prepared by the investigators). The
Medical Research Council Scale was used to determine the severity of
dyspnea in the patients included in the study. Primary outcomes included
respiratory rate, oxygen saturation, arterial blood gas parameters,
posteroanterior chest X-ray, and evaluation of postoperative pulmonary
complications development. Secondary outcomes included the mechanical
ventilation time, length of intensive care unit stay, and length of
hospital stay. RESULT(S): The incidence of postoperative pulmonary
complications was 3.1% and 23.5% (p < 0.05) in the deep breathing and
control groups, respectively. The mechanical ventilation time, length of
hospital stay, and length of stay in the intensive care unit were
significantly shorter in the deep breathing group (p < 0.05). In the deep
breathing group, the mean SpO2 values evaluated before surgery, on the
first day in the Cardiovascular Surgery Unit, and on the day of discharge
were significantly higher than the control group (p < 0.05).
 CONCLUSION(S): Deep breathing exercises with an incentive spirometer
initiated in the preoperative period contribute to a reduction in
postoperative pulmonary complication rates, shortening of mechanical
ventilation time, length of stay in the intensive care unit, length of
hospital stay, and improvement of pre- and postoperative oxygenation.
TRIAL REGISTRATION: The trial was registered on June 17, 2022, at
https://www. CLINICALTRIALS: gov/ , registration number
NCT05428722. Copyright © 2025. The Author(s).

<58>
Accession Number
2032511940
Title
Impact of nondiameter aortic indices on surgical eligibility: Results from
the Treatment in Thoracic Aortic Aneurysm: Surgery Versus Surveillance
(TITAN: SvS) randomized controlled trial.
Source
Journal of Thoracic and Cardiovascular Surgery. (no pagination), 2024.
Date of Publication: 2024.
Author
Dagher O.; Appoo J.J.; Herget E.; Atoui R.; Baeza C.; Brinkman W.;
Bozinovski J.; Chu M.W.A.; Dagenais F.; Demers P.; Desai N.; El-Hamamsy
I.; Estrera A.; Grau J.B.; Hughes G.C.; Jassar A.; Kachroo P.; Lachapelle
K.; Ouzounian M.; Patel H.J.; Pozeg Z.; Tseng E.; Whitlock R.; Guo M.H.;
Boodhwani M.
Institution
(Dagher, Appoo) Department of Cardiac Sciences, Libin Cardiovascular
Institute, Calgary, AB, Canada
(Dagher) Department of Biomedical Sciences, Faculty of Medicine,
Universite de Montreal, Montreal, QC, Canada
(Herget) Department of Diagnostic Imaging, University of Calgary, Calgary,
AB, Canada
(Atoui) Division of Cardiothoracic Surgery, Northern Ontario School of
Medicine, Sudbury, ON, Canada
(Baeza) Division of Cardiac Surgery, Harrington Heart and Vascular
Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio,
United States
(Brinkman) Division of Cardiothoracic Surgery, Baylor Scott & White
Health, Dallas, Tex, United States
(Bozinovski) Division of Cardiothoracic Surgery, The Ohio State University
Wexner Medical Center, Columbus, OH, United States
(Chu) Division of Cardiac Surgery, Western University, London Health
Sciences Centre, London, ON, Canada
(Dagenais) Department of Cardiac Surgery, Quebec Heart and Lung Institute,
Quebec, QC, Canada
(Demers) Department of Surgery, Montreal Heart Institute, Montreal, QC,
Canada
(Desai) Division of Cardiothoracic Surgery, University of Pennsylvania,
Philadelphia, Pa, United States
(El-Hamamsy) Division of Cardiothoracic Surgery, Mount Sinai Hospital, New
York, NY, United States
(Estrera) Department of Cardiothoracic Surgery, McGovern Medical School at
UTHealth Houston, Houston, Tex, United States
(Grau) Division of Cardiothoracic Surgery, The Valley Hospital, Ridgewood,
NJ, United States
(Hughes) Division of Cardiothoracic Surgery, Duke University Medical
Center, Durham, NC, United States
(Jassar) Division of Cardiothoracic Surgery, Massachusetts General
Hospital, Boston, Mass, United States
(Kachroo) Division of Cardiothoracic Surgery, Washington University School
of Medicine, St Louis, Mo, United States
(Lachapelle) Division of Cardiac Surgery, McGill University Health Centre,
Montreal, QC, Canada
(Ouzounian) Division of Cardiovascular Surgery, Toronto General Hospital,
Toronto, ON, Canada
(Patel) Division of Cardiiothoracic Surgery, University of Michigan
Hospital, Ann Arbor, Mich, United States
(Pozeg) Division of Cardiac Surgery, New Brunswick Heart Centre, Saint
John, New-Brunswick, Canada
(Tseng) Division of Cardiothoracic Surgery, University of California, San
Francisco Medical Center, San Francisco, Calif, United States
(Whitlock) Division of Cardiac Surgery, Population Health Research
Institute, Hamilton, ON, Canada
(Guo, Boodhwani) Division of Cardiac Surgery, University of Ottawa Heart
Institute, Ottawa, ON, Canada
Publisher
Elsevier Inc.
Abstract
Objectives: Traditional criterion for intervention on an asymptomatic
ascending aortic aneurysm has been a maximal aortic diameter of 5.5 cm or
more. The 2022 American College of Cardiology/American Heart Association
aortic guidelines adopted cross-sectional aortic area/height ratio, aortic
size index, and aortic height index as alternate parameters for surgical
intervention. The objective of this study was to evaluate the impact of
using these newer indices on patient eligibility for surgical intervention
in a prospective, multicenter cohort with moderate-sized ascending aortic
aneurysms between 5.0 and 5.4 cm. Method(s): Patients enrolled from
2018 to 2023 in the randomization or registry arms of the multicenter
trial, Treatment In Thoracic Aortic aNeurysm: Surgery versus Surveillance,
were included in the study. Clinical data were captured prospectively in
an online database. Imaging data were derived from a core computed
laboratory. Result(s): Among the 329 included patients, 20% were
female. Mean age was 65.0 +/- 11.6 years, and mean maximal aortic diameter
was 50.8 +/- 3.9 mm. In the one-third of all patients (n = 109) who met
any 1 of the 3 criteria (ie, aortic size index >=3.08 cm/m2,
aortic height index >=3.21 cm/m, or cross-sectional aortic area/height >=
10 cm2/m), their mean maximal aortic diameter was 52.5 +/- 0.52
mm. Alternate criteria were most commonly met in women compared with men:
20% versus 2% for aortic size index (P < .001), 39% versus 5% for aortic
height index (P < .001), and 39% versus 21% for cross-sectional aortic
area/height (P = .002), respectively. Conclusion(s): One-third of
patients in Treatment In Thoracic Aortic aNeurysm: Surgery versus
Surveillance would meet criteria for surgical intervention based on novel
parameters versus the classic definition of diameter 5.5 cm or more.
Surgical thresholds for aortic size index, aortic height index, or
cross-sectional aortic area/height ratio are more likely to be met in
female patients compared with male patients. Copyright © 2024 The
American Association for Thoracic Surgery

<59>
Accession Number
2032545323
Title
Trends in safety of catheter-based electrophysiology procedures in the
last 2 decades: A meta-analysis.
Source
Heart Rhythm. 21(9) (pp 1718-1726), 2024. Date of Publication: 01 Sep
2024.
Author
Oates C.P.; Basyal B.; Whang W.; Reddy V.Y.; Koruth J.S.
Institution
(Oates, Basyal) MedStar Heart and Vascular Institute, Georgetown
University-Washington Hospital Center, Washington, DC, United States
(Oates, Whang, Reddy, Koruth) Helmsley Center for Cardiac
Electrophysiology, Icahn School of Medicine at Mount Sinai, New York, New
York, United States
Publisher
Elsevier B.V.
Abstract
Background: Rapid technologic development and expansion of procedural
expertise have led to widespread proliferation of catheter-based
electrophysiology procedures. It is unclear whether these advances come at
cost to patient safety. Objective(s): This meta-analysis aimed to
assess complication rates after modern electrophysiology procedures during
the lifetime of the procedures. Method(s): A comprehensive search was
performed to identify relevant data published before May 30, 2023. Studies
were included if they met the following inclusion criteria: prospective
trials or registries, including comprehensive complications data; and
patients undergoing atrial fibrillation ablation, ventricular
tachyarrhythmia ablation, leadless cardiac pacemaker implantation, and
percutaneous left atrial appendage occlusion. Pooled incidences of
procedure-related complications were individually assessed by random
effects models to account for heterogeneity. Temporal trends in
complications were investigated by clustering trials by publication year
(2000-2018 vs 2019-2023). Result(s): A total of 174 studies (43,914
patients) met criteria for analysis: 126 studies of atrial fibrillation
ablation (n = 24,057), 25 studies of ventricular tachyarrhythmia ablation
(n = 1781), 21 studies of leadless cardiac pacemaker (n = 8896), and 18
studies of left atrial appendage occlusion (n = 9180). The pooled
incidences of serious procedure-related complications (3.49% [2000-2018]
vs 3.05% [2019-2023]; P < .001), procedure-related stroke (0.46% vs 0.28%;
P = .002), pericardial effusion requiring intervention (1.02% vs 0.83%; P
= .037), and procedure-related death (0.15% vs 0.06%; P = .003)
significantly decreased over time. However, there was no significant
difference in the incidence of vascular complications over time (1.86% vs
1.88%; P = .888). Conclusion(s): Despite an increase in cardiac
electrophysiology procedures, procedural safety has improved over
time. Copyright © 2024 Heart Rhythm Society

<60>
Accession Number
2037330610
Title
Effect of del Nido Cardioplegia on Isolated Coronary Artery Bypass
Grafting: A Study-level Meta-analysis.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2025.
Date of Publication: 2025.
Author
Yamashita Y.; Baudo M.; Magouliotis D.E.; Sicouri S.; Wertan M.A.C.;
Spragan D.D.; Torregrossa G.; Ramlawi B.; Sutter F.P.
Institution
(Yamashita, Wertan, Spragan, Torregrossa, Ramlawi, Sutter) Department of
Cardiothoracic Surgery, Lankenau Heart Institute, Wynnewood, PA, United
States
(Yamashita, Baudo, Magouliotis, Sicouri, Ramlawi) Department of
Cardiothoracic Surgery Research, Lankenau Institute for Medical Research,
Wynnewood, PA, United States
Publisher
W.B. Saunders
Abstract
The purpose of this study was to evaluate the effect of del Nido
cardioplegia versus conventional cardioplegic solutions on early outcomes
of isolated coronary artery bypass grafting (CABG). PubMed, Scopus, and
the Cochrane Central Register of Controlled Trials were searched through
July 2024 to conduct a meta-analysis for a comparison between del Nido and
other cardioplegic solutions in isolated CABG. Major end points of the
study included operative mortality and morbidities. A random effects model
was used to estimate the pooled effect size. For subgroup analyses,
meta-analyses were conducted for outcomes derived from either randomized
controlled-trials, propensity score analysis, or multivariable analysis.
Twenty-four studies met our eligibility criteria, including 4 randomized
controlled trials and 5 propensity score-matched studies with a total of
34,737 patients. Operative mortality was not significantly associated with
cardioplegic solutions (del Nido vs other solutions; p = 0.262). The
incidence of postoperative stroke, reoperation, deep wound infection, and
atrial fibrillation was also comparable between the 2 groups. The
incidence of postoperative myocardial infarction and renal failure was
significantly lower in the del Nido group with a pooled odds ratio of 0.43
(95% confidence interval, 0.24-0.77) and 0.61 (95% confidence interval,
0.45-0.81), respectively. Subgroup analyses also demonstrated these
significant differences. In patients undergoing isolated CABG, del Nido
cardioplegia provides comparable mortality compared with other
cardioplegic solutions. Del Nido solution was significantly protective
against myocardial infarction and renal failure. Copyright © 2025
Elsevier Inc.

<61>
Accession Number
2032453618
Title
Retraction Note: Effects of bilateral Pecto-intercostal Fascial Block for
perioperative pain management in patients undergoing open cardiac surgery:
a prospective randomized study (BMC Anesthesiology, (2021), 21, (175),
10.11 86/s 12871-021-01391-w).
Source
BMC Anesthesiology. 24(1) (no pagination), 2024. Article Number: 445. Date
of Publication: 01 Dec 2024.
Author
Zhang Y.; Gong H.; Zhan B.; Chen S.
Institution
(Zhang, Gong, Chen) Department of Anesthesiology, First Affiliated
Hospital of Nanchang University, 17 Yong wai zheng Street, Jiangxi,
Nanchang, China
(Zhan) Department of cardiology, The second Affiliated Hospital of
Nanchang University, NO.1 minde Street, Jiangxi, Nanchang, China
Publisher
BioMed Central Ltd
Abstract
The Editor has retracted this article. After publication, concerns were
raised regarding the reporting of this randomised controlled study. An
investigation has found that there are significant differences between the
age range in the inclusion criteria stated in the trial registration
record and those reported in this article. The authors have been unable to
sufficiently justify these differences. Therefore, the Editor no longer
has confidence in the results and conclusions presented. None of the
authors have responded to correspondence from the Editor about this
retraction. Copyright © The Author(s) 2024.

<62>
Accession Number
2037315175
Title
Tricuspid Transcatheter Edge-to-Edge Repair in Patients With Transvalvular
CIED Leads: The TRILUMINATE Pivotal Trial.
Source
JACC: Clinical Electrophysiology. (no pagination), 2025. Date of
Publication: 2025.
Author
Naik H.; Price M.J.; Kapadia S.; Whisenant B.K.; Tadros P.; Makkar R.;
Asgar A.W.; Fam N.; Tang G.H.L.; Mehta S.R.; Byrne T.; Singh G.; Panaich
S.S.; Peterman K.; Trusty P.M.; Hamid N.; Hahn R.T.; Adams D.H.; Sorajja
P.
Institution
(Naik) Arizona Cardiovascular Research Center, Phoenix, AZ, United States
(Price) Scripps Clinic, La Jolla, CA, United States
(Kapadia) Cleveland Clinic Foundation. Cleveland, OH, United States
(Whisenant) Intermountain Medical Center, Murray, UT, United States
(Tadros) Kansas University Medical Center, Kansas City, KS, United States
(Makkar) Cedars-Sinai Medical Center, Los Angeles, CA, United States
(Asgar) Montreal Heart Institute, Montreal, QC, Canada
(Fam) St. Micheal's Hospital, Toronto, ON, Canada
(Tang, Adams) Mount Sinai Hospital, New York, NY, United States
(Mehta) Hamilton Health Science Centre, Hamilton, ON, Canada
(Byrne) Phoenix Cardiovascular Research Group, Phoenix, AZ, United States
(Singh) University of California, Davis Medical Center, Sacramento, CA,
United States
(Panaich) Swedish Medical Center, Seattle, WA, United States
(Peterman, Trusty) Abbott Structural Heart, Santa Clara, CA, United States
(Hamid, Sorajja) Abbott Northwestern Hospital, Minneapolis, MN, United
States
(Hahn) NewYork-Presbyterian/Columbia University Medical Center, New York,
NY, United States
Publisher
Elsevier Inc.
Abstract
Background: Patients with tricuspid regurgitation (TR) frequently have
transvalvular cardiac implantable electronic device (CIEDs).
 Objective(s): The aim of this study was to determine the safety and
efficacy of tricuspid transcatheter edge-to-edge repair in patients with
transvalvular CIED leads. Method(s): The TRILUMINATE (Trial to
Evaluate Cardiovascular Outcomes in Patients Treated With the Tricuspid
Valve Repair System) Pivotal Trial (NCT03904147) is an international
randomized, controlled trial in symptomatic subjects with severe TR.
Subjects with CIED leads were screened by an eligibility committee prior
to inclusion into the randomized or single-arm cohorts. Safety events were
adjudicated by an independent review committee. All echocardiograms were
analyzed by an independent core laboratory. Result(s): A total of 98
subjects (of 469) with attempted TriClip procedures had transvalvular CIED
leads. CIED+ subjects were older (80.2 +/- 8.6 years vs 78.2 +/- 7.6
years; P = 0.02), with a higher prevalence of renal disease (46.9% vs
31.5%; P = 0.004) and lower health status (Kansas City Cardiomyopathy
Questionnaire overall summary score 51.9 +/- 21.0 vs 55.0 +/- 23.1) at
baseline compared with CIED- subjects. Slightly fewer clips were implanted
in CIED+ subjects (mean 1.9) than in CIED- subjects (mean 2.2) (P =
0.0018). Procedural times were significantly shorter in CIED+ subjects
(132.9 +/- 63.3 minutes vs 155.9 +/- 71.9 minutes; P = 0.0043) although
greater in those with lead-induced TR (149.5 +/- 87.5 minutes). Major
adverse events (1.0% vs 1.1%) and major bleeding (3.1% vs 3.0%) were
infrequent in CIED+ and CIED- subjects. At 30 days, TR reduction to
moderate or less was similar in CIED+ and CIED- subjects (88% vs 87%) and
was sustained out to 1 year in the majority of subjects (81% vs 84%).
Compared with baseline, Kansas City Cardiomyopathy Questionnaire overall
summary score significantly improved through 1 year in CIED+ subjects
(18.7 +/- 22.6; P < 0.0001) and CIED- subjects (16.8 +/- 22.6; P <
0.0001). Heart failure symptoms were reduced in both groups at 30 days,
with 85% of CIED+ subjects and 87% of CIED- subjects in NYHA functional
class I or II. There were no differences in mortality, heart failure
hospitalization, and need for tricuspid valve surgery or intervention
between groups. No lead revisions, removals, or replacements were reported
through follow-up. Conclusion(s): Tricuspid transcatheter
edge-to-edge repair with the TriClip system was safe and effective in
selected CIED+ subjects and did not affect CIED function. CIED+ subjects
experienced similar TR reduction and quality-of-life improvements as CIED-
subjects. Future work should define the treatable scope of patients with
transvalvular CIED leads. (TRILUMINATE Pivotal Trial;
NCT03904147) Copyright © 2025

<63>
Accession Number
2037315022
Title
Best evidence topic: Transcatheter aortic valve implantation in
asymptomatic aortic stenosis patients.
Source
Cirugia Cardiovascular. (no pagination), 2025. Date of Publication: 2025.
Author
Martin Gutierrez E.; Maiorano P.; Castillo Pardo L.; Meana Fernandez B.;
Ramos Barragan B.; Gualis Cardona J.; Castano Ruiz M.; Martinez Comendador
J.M.; Garrido Jimenez J.M.
Institution
(Martin Gutierrez, Maiorano, Castillo Pardo, Meana Fernandez, Ramos
Barragan, Gualis Cardona, Castano Ruiz) Servicio de Cirugia Cardiaca,
Complejo Asistencial Universitario de Leon, Leon, Spain
(Martinez Comendador) Servicio de Cirugia Cardiaca, Complexo Hospitalario
Universitario de A Coruna (CHUAC), A Coruna, Spain
(Garrido Jimenez) Servicio de Cirugia Cardiaca, Hospital Universitario
Virgen de las Nieves, Granada, Spain
Publisher
Sociedad Espanola de Cirugia Cardiovascular y Endovascular (SECCE)
Abstract
Background: Transcatheter aortic valve implantation (TAVI) has become the
most frequent option for severe aortic stenosis treatment. Patients with
severe aortic stenosis may present an increased risk of mortality in the
asymptomatic phase. Furthermore, the progression of their heart disease
may have prognostic implications. It is proposed to carry out a
bibliographic review to assess the benefit of TAVI in this context.
 Method(s): A systematic search in Pubmed and Cochrane was conducted,
identifying comparative studies on surgery and/or TAVI versus conservative
management in asymptomatic patients. Thus, an algorithm of better
management of patients with severe aortic stenosis would be developed
according to the available evidence. Result(s): After the selection
of papers and elimination of duplicates, 34 studies were full-text
analyzed, among which we remark: 6 meta-analyses, 4 reviews, 14 original
articles and 4 ongoing clinical trials were identified. Early surgery was
unanimously superior to conservative management in terms of survival. In
the case of TAVI, two studies demonstrated a better prognosis for
asymptomatic patients compared to symptomatic patients when their valve
disease was corrected with TAVI, and a sub-analysis of the Evolut Low Risk
trial demonstrated superior survival results for TAVI compared to surgery
and conservative treatment. Conclusion(s): In the absence of a solid
evidence, TAVI can be considered a valid treatment alternative for
patients with asymptomatic aortic stenosis, although this indication
relies on indirect evidence. More research is needed in this
field. Copyright © 2024 Sociedad Espanola de Cirugia
Cardiovascular y Endovascular

<64>
Accession Number
2033038619
Title
Advances in understanding the effects of cardiopulmonary bypass on gut
microbiota during cardiac surgery.
Source
International Journal of Artificial Organs. (no pagination), 2025. Date
of Publication: 2025.
Author
Zhang Y.; Luo W.; Zhao M.; Li Y.; Wu X.
Institution
(Zhang, Luo, Li, Wu) Department of Cardiac surgery, The Second Hospital &
Clinical Medical School, Lanzhou University, Lanzhou, China
(Zhao) Department of Cardiology, First Hospital of Lanzhou University,
Lanzhou University, Lanzhou, China
Publisher
SAGE Publications Ltd
Abstract
Cardiopulmonary bypass (CPB) is an indispensable technique in cardiac
surgery; however, its impact on gut microbiota and metabolites remains
insufficiently studied. CPB may disrupt the intestinal mucosal barrier,
altering the composition and function of gut microbiota, thereby
triggering local immune responses and systemic inflammation, which may
lead to postoperative complications. This narrative review examines
relevant literature from PubMed, Web of Science, Google Scholar, and CNKI
databases over the past decade. Keywords such as "gut microbiota,"
"cardiopulmonary bypass," "cardiac surgery," and "postoperative
complications" were employed, with Boolean operators used to refine the
search results. The review examines changes in gut microbiota before and
after CPB, their role in postoperative complications, and potential
strategies for modulation to improve outcomes. Copyright © The
Author(s) 2025.

<65>
Accession Number
646396879
Title
Effect of injection of mononuclear autologous cells during CABG on
improvement of infarcted tissue in patients with ischemic cardiomyopathy.
Source
Iranian Journal of Nuclear Medicine. Conference: 23rd Iranian Nuclear
Medicine Annual Congress. Tehran Iran, Islamic Republic of. 28(Supplement
1) (pp 8), 2020. Date of Publication: 01 Nov 2020.
Author
Banezhad F.; Dabbagh V.R.; Abbasi M.; Sadeghi R.; Vakilian F.
Institution
(Banezhad, Dabbagh, Abbasi, Sadeghi, Vakilian) Nuclear Medicine Research
Center, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic
Republic of
Publisher
Tehran University of Medical Sciences
Abstract
Background: Ischemic cardiomyopathy means reduced ability of the heart to
pump blood correctly due to the lesion following cardiac infarction, in
which systolic function of the heart is deteriorated progressively.
 Objective(s): One of the novel treatments that is used today and has
drawn lots of attention to itself is using stem cells and evaluation of
its effect on cardiac viability and function was the goal of this study.
 Method(s): This study was performed by randomized sampling on 18
patients with ischemic heart failure. Patients in two groups of case group
(CABG with cellular therapy) and control group (only CABG) were evaluated
with myocardial perfusion scan and echocardiography. Result(s): In
qualitative interpretation of viability, there was no significant
difference between the two groups in initial and follow-up scans
(p-value>0.05). In qualitative interpretation of the motions of the
segments, there was no significant difference between the two groups in
initial and 6-month scans, as well as during follow-up period
(p-value>0.05). Also in quantitative evaluation, about ESV, EDV and EF the
only significant difference was in 6-month scan (p-values were 0.017,
0.045 and 0.01 respectively), in which the results were better in the
control group. In quantitative evaluation of motion, generally there was
only significant difference on 6-month scan (pvalue: 0.017), in which the
result was better in the control group and in segmental evaluation, there
was no significant difference between the two groups (p-value>0.05). About
thickness, in general and segmental evaluations, there was no significant
difference between the two groups (pvalue> 0.05). About perfusion scores,
in general and segmental evaluations, there was no significant difference
between the two groups (p-value>0.05). In the evaluations of TPD
parameter, summed Raws, summed Severities and summed of Extents of the
infarcted segments, there was no significant difference between the two
groups in initial and follow-up scans (p-value>0.05). In echocardiographic
parameters, about EF, there were only significant differences between the
two groups in initial and 3-month echocardiographies (p-values were 0.012
and 0.015 respectively), in which the results were better in the control
group. There were no significant differences in ESV, LVEDD and RVEDD
between the two groups in 3-month and 6-month echocardiographies (pvalue>
0.05). Conclusion(s): Injection of mononuclear cells in patients with
ischemic heart failure has no effect on viability, motion and thickness of
myocardium, as well as functional factors like EF, ESV, EDV, RVEDD and
LVEDD.

EPICORE Embase Updates

Saturday, February 15, 2025

EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

No comments:

Post a Comment

Followers

Blog Archive

About Me